CA2511521A1 - Drug delivery from rapid gelling polymer composition - Google Patents
Drug delivery from rapid gelling polymer composition Download PDFInfo
- Publication number
- CA2511521A1 CA2511521A1 CA002511521A CA2511521A CA2511521A1 CA 2511521 A1 CA2511521 A1 CA 2511521A1 CA 002511521 A CA002511521 A CA 002511521A CA 2511521 A CA2511521 A CA 2511521A CA 2511521 A1 CA2511521 A1 CA 2511521A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- drug
- analogue
- derivative
- sulfhydryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract 124
- 229920000642 polymer Polymers 0.000 title claims abstract 13
- 238000012377 drug delivery Methods 0.000 title claims abstract 5
- 239000003814 drug Substances 0.000 claims 88
- 229940079593 drug Drugs 0.000 claims 88
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 75
- 150000001875 compounds Chemical class 0.000 claims 51
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 31
- 239000007788 liquid Substances 0.000 claims 23
- 238000000034 method Methods 0.000 claims 15
- -1 succinimidyl Chemical class 0.000 claims 14
- 230000002378 acidificating effect Effects 0.000 claims 13
- 238000001727 in vivo Methods 0.000 claims 10
- 108010035532 Collagen Proteins 0.000 claims 8
- 102000008186 Collagen Human genes 0.000 claims 8
- 229920001436 collagen Polymers 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 229920001281 polyalkylene Polymers 0.000 claims 8
- 229940125782 compound 2 Drugs 0.000 claims 7
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 6
- 239000007853 buffer solution Substances 0.000 claims 6
- 230000007935 neutral effect Effects 0.000 claims 6
- 239000000843 powder Substances 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 5
- 229940043355 kinase inhibitor Drugs 0.000 claims 5
- 239000000872 buffer Substances 0.000 claims 4
- 229940125904 compound 1 Drugs 0.000 claims 4
- 230000002209 hydrophobic effect Effects 0.000 claims 4
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 3
- 239000008363 phosphate buffer Substances 0.000 claims 3
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 2
- 101800003838 Epidermal growth factor Proteins 0.000 claims 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 102000029749 Microtubule Human genes 0.000 claims 2
- 108091022875 Microtubule Proteins 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims 2
- 239000012062 aqueous buffer Substances 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 229940116977 epidermal growth factor Drugs 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 210000004688 microtubule Anatomy 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 150000007970 thio esters Chemical class 0.000 claims 2
- 150000003568 thioethers Chemical class 0.000 claims 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 claims 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 1
- AOLNDUQWRUPYGE-UHFFFAOYSA-N 1,4-dioxepan-5-one Chemical compound O=C1CCOCCO1 AOLNDUQWRUPYGE-UHFFFAOYSA-N 0.000 claims 1
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 claims 1
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 claims 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims 1
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 claims 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 1
- 229940122858 Elastase inhibitor Drugs 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims 1
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims 1
- 229940122331 Fibrinogen antagonist Drugs 0.000 claims 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 229940123692 GPIIb IIIa receptor antagonist Drugs 0.000 claims 1
- 229940118547 Guanylate cyclase stimulant Drugs 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 229940123034 Heat shock protein 90 antagonist Drugs 0.000 claims 1
- 229940122296 IKK2 inhibitor Drugs 0.000 claims 1
- 229940121740 Inosine monophosphate dehydrogenase inhibitor Drugs 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 1
- 102000002569 MAP Kinase Kinase 4 Human genes 0.000 claims 1
- 108010068304 MAP Kinase Kinase 4 Proteins 0.000 claims 1
- 229940122696 MAP kinase inhibitor Drugs 0.000 claims 1
- 229940123313 MCP-1 antagonist Drugs 0.000 claims 1
- 229940124761 MMP inhibitor Drugs 0.000 claims 1
- 108010008364 Melanocortins Proteins 0.000 claims 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 108091008606 PDGF receptors Proteins 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 229940121927 Phospholipase A1 inhibitor Drugs 0.000 claims 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 1
- 229940120646 Platelet-derived growth factor receptor kinase inhibitor Drugs 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims 1
- 229940123690 Raf kinase inhibitor Drugs 0.000 claims 1
- 229940122756 Retinoic acid receptor antagonist Drugs 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- 108700012920 TNF Proteins 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 102100035140 Vitronectin Human genes 0.000 claims 1
- 108010031318 Vitronectin Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002559 chemokine receptor antagonist Substances 0.000 claims 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003602 elastase inhibitor Substances 0.000 claims 1
- 102000015694 estrogen receptors Human genes 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229940126864 fibroblast growth factor Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 239000002865 melanocortin Substances 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical group O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 239000002077 nanosphere Substances 0.000 claims 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 1
- NETARJWZTMGMRM-KJHLVSCNSA-N peloruside A Natural products CC[C@@H](CO)C=C(C)[C@@H]1C[C@H](C[C@H](O)C(C)(C)[C@@]2(O)O[C@@H](C[C@@H](OC)[C@H](O)C(=O)O1)C[C@@H](OC)[C@H]2O)OC NETARJWZTMGMRM-KJHLVSCNSA-N 0.000 claims 1
- NETARJWZTMGMRM-JRTPPQMASA-N peloruside A Chemical compound C1[C@H](OC)[C@@H](O)C(=O)O[C@@H](C(\C)=C/[C@@H](CO)CC)C[C@H](OC)C[C@@H](O)C(C)(C)[C@@]2(O)[C@@H](O)[C@@H](OC)C[C@@H]1O2 NETARJWZTMGMRM-JRTPPQMASA-N 0.000 claims 1
- 239000003614 peroxisome proliferator Substances 0.000 claims 1
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 claims 1
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 1
- 239000003909 protein kinase inhibitor Substances 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 claims 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 claims 1
- 229960002110 vincristine sulfate Drugs 0.000 claims 1
- 229960004355 vindesine Drugs 0.000 claims 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
- 208000031737 Tissue Adhesions Diseases 0.000 abstract 2
- 230000003416 augmentation Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000023597 hemostasis Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000000565 sealant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/041—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1213—Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/434—Inhibitors, antagonists of enzymes
Abstract
Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For example, the compositions are useful as tissue sealants, in promoting hemostasis, in effecting tissue adhesion, in providing tissue augmentation, and in the prevention of surgical adhesions.
Claims (126)
1. A biocompatible gel-forming drug-delivering composition for in vivo administration, comprising:
a drug;
a first component comprising at least one sulfhydryl group-containing compound in a liquid medium having an alkaline pH, wherein said sulfhydryl group-containing compound is given by the formula Compound1 -(SH)m, wherein m >=2; and a second component comprising at least one sulfhydryl reactive group-containing compound in either a liquid medium having a neutral or acidic pH or in powder form, wherein said sulfhydryl reactive group-containing compound is given by the formula Compound2 -Y n, wherein Y is a sulfhydryl reactive group and wherein n>=2;
wherein at least one of the first or second components is a polyalkylene oxide and wherein the sulfhydryl groups and the sulfhydryl reactive groups react with one another to form covalent bonds therebetween when said components are mixed together to form a gel in less than one minute.
a drug;
a first component comprising at least one sulfhydryl group-containing compound in a liquid medium having an alkaline pH, wherein said sulfhydryl group-containing compound is given by the formula Compound1 -(SH)m, wherein m >=2; and a second component comprising at least one sulfhydryl reactive group-containing compound in either a liquid medium having a neutral or acidic pH or in powder form, wherein said sulfhydryl reactive group-containing compound is given by the formula Compound2 -Y n, wherein Y is a sulfhydryl reactive group and wherein n>=2;
wherein at least one of the first or second components is a polyalkylene oxide and wherein the sulfhydryl groups and the sulfhydryl reactive groups react with one another to form covalent bonds therebetween when said components are mixed together to form a gel in less than one minute.
2. The composition of claim 1, wherein m and n are each 4.
3. The composition of claim 1, wherein m and n are each 12.
4. The composition of claim 1, wherein the first component is a polyalkylene oxide.
5. The composition of claim 1, wherein the second component is a polyalkylene oxide.
6. The composition of claim 1, wherein the first and second components are polyalkylene oxides.
7. The composition of claim 6, wherein the polyalkylene oxides are polyethylene glycol.
8. The composition of claim 1, wherein only one of the first or second components is a polyalkylene oxide.
9. The composition of claim 8, wherein one of the components is a polyalkylene oxide and the other component is a functionally activated succinimidyl or maleimidyl compound which is not a polymer.
10. The composition of claim 1, wherein the covalent bonds are thioester linkages.
11. The composition of claim 1, wherein the covalent bonds are thioether linkages.
12. The composition of claim 1, wherein the covalent bonds are sulfhydryl linkages.
13. The composition of claim 1, wherein the drug is hydrophobic.
14. The composition of claim 1, wherein the drug is an angiogenesis inhibitor.
15. The composition of claim 1, wherein the drug is a 5-Lipoxygenase inhibitor or antagonist.
16. The composition of claim 1, wherein the drug is a chemokine receptor antagonist.
17. The composition of claim 1, wherein the drug is a cell cycle inhibitor or an analogue or derivative thereof.
18. The composition of claim 17, wherein the cell cycle inhibitor is a microtubule stabilizing agent.
19. The composition of claim 18, wherein the microtubule stabilizing agent is paclitaxel, docetaxel, or Peloruside A.
20. The composition of claim 17, wherein the cell cycle inhibitor is a taxane.
21. The composition of claim 18, wherein the taxane is paclitaxel or an analogue or derivative thereof.
22. The composition of claim 17, wherein the cell cycle inhibitor is an antimetabolite, an alkylating agent, or a vinca alkaloid.
23. The composition of claim 22, wherein the vinca alkaloid is vinblastine, vincristine, vincristine sulfate, vindesine, vinorelbine, or an analogue or derivative thereof.
24. The composition of claim 17, wherein the cell cycle inhibitor is camptothecin or an analogue or derivative thereof.
25. The composition of claim 17, wherein the cell cycle inhibitor is selected from the group consisting of mitoxantrone, etoposide, 5-fluorouracil, doxorubicin, methotrexate, Mitomycin-C, CDK-2 inhibitors, and analogues and derivatives thereof.
26. The composition of claim 1, wherein the drug is a cyclin dependent protein kinase inhibitor or an analogue or derivative thereof.
27. The composition of claim 1, wherein the drug is an EGF
(epidermal growth factor) kinase inhibitor or an analogue or derivative thereof.
(epidermal growth factor) kinase inhibitor or an analogue or derivative thereof.
23. The composition of claim 1, wherein the drug is an elastase inhibitor or an analogue or derivative thereof.
29. The composition of claim 1, wherein the drug is a factor Xa inhibitor or an analogue or derivative thereof.
30. The composition of claim 1, wherein the drug is a farnesyltransferase inhibitor or an analogue or derivative thereof.
31. The composition of claim 1, wherein the drug is a fibrinogen antagonist or an analogue or derivative thereof.
32. The composition of claim 1, wherein the drug is a guanylate cyclase stimulant or an analogue or derivative thereof.
33. The composition of claim 1, wherein the drug is a heat shock protein 90 antagonist or an analogue or derivative thereof.
34. The composition of claim 1, wherein the drug is an HMGCoA reductase inhibitor or an analogue or derivative thereof.
35. The composition of claim 1, wherein the drug is a hydroorotate dehydrogenase inhibitor or an analogue or derivative thereof.
36. The composition of claim 1, wherein the drug is an IKK2 inhibitor or an analogue or derivative thereof.
37. The composition of claim 1, wherein the drug is an IL-1, ICE, or IRAK antagonist or an analogue or derivative thereof.
38. The composition of claim 1, wherein the drug is an IL-4 agonist or an analogue or derivative thereof.
39. The composition of claim 1, wherein the drug is an immunomodulatory is rapamycin, tacrolimus, everolimus, biolimus, or an analogue or derivative thereof.
40. The composition of claim 1, wherein the drug is an inosine monophosphate dehydrogenase inhibitor or an analogue or derivative thereof.
41. The composition of claim 1, wherein the drug is a leukotreine inhibitor or an analogue or derivative thereof.
42. The composition of claim 1, wherein the drug is a MCP-1 antagonist or an analogue or derivative thereof.
43. The composition of claim 1, wherein the drug is a MMP
inhibitor or an analogue or derivative thereof.
inhibitor or an analogue or derivative thereof.
44. The composition of claim 1, wherein the drug is a NF
kappa B inhibitor or an analogue or derivative thereof.
kappa B inhibitor or an analogue or derivative thereof.
45. The composition of claim 1, wherein the drug is a NO
antagonist or an analogue or derivative thereof.
antagonist or an analogue or derivative thereof.
46. The composition of claim 1, wherein the drug is a P38 MAP
kinase inhibitor or an analogue or derivative thereof.
kinase inhibitor or an analogue or derivative thereof.
47. The composition of claim 1, wherein the drug is a phosphodiesterase inhibitor or an analogue or derivative thereof.
48. The composition of claim 1, wherein the drug is a TGF beta Inhibitor or an analogue or derivative thereof.
49. The composition of claim 1, wherein the drug is a thromboxane A2 antagonist or an analogue or derivative thereof.
50. The composition of claim 1, wherein the drug is a TNFa Antagonist, a TACE, or an analogue or derivative thereof.
51. The composition of claim 1, wherein the drug is a tyrosine kinase inhibitor or an analogue or derivative thereof.
52. The composition of claim 1, wherein the drug is a vitronectin inhibitor or an analogue or derivative thereof.
53. The composition of claim 1, wherein the drug is a fibroblast growth factor inhibitor or an analogue or derivative thereof.
54. The composition of claim 1, wherein the drug is a protein kinase inhibitor or an analogue or derivative thereof.
55. The composition of claim 1, wherein the drug is a PDGF
receptor kinase inhibitor or an analogue or derivative thereof.
receptor kinase inhibitor or an analogue or derivative thereof.
56. The composition of claim 1, wherein the drug is an endothelial growth factor receptor kinase inhibitor or an analogue or derivative thereof.
57. The composition of claim 1, wherein the drug is a retinoic acid receptor antagonist or an analogue or derivative thereof.
58. The composition of claim 1, wherein the drug is a platelet derived growth factor receptor kinase inhibitor or an analogue or derivative thereof.
59. The composition of claim 1, wherein the drug is a fibrinogin antagonist or an analogue or derivative thereof.
60. The composition of claim 1, wherein the drug is an antimycotic agent or an analogue or derivative thereof.
61. The composition of claim 1, wherein the drug is a bisphosphonate or an analogue or derivative thereof.
62. The composition of claim 1, wherein the drug is a phospholipase A1 inhibitor or an analogue or derivative thereof.
63. The composition of claim 1, wherein the drug is a histamine H1/H2/H3 receptor antagonist or an analogue or derivative thereof.
64. The composition of claim 1, wherein the drug is a macrolide antibiotic or an analogue or derivative thereof.
65. The composition of claim 1, wherein the drug is an GPIIb IIIa receptor antagonist or an analogue or derivative thereof.
66. The composition of claim 1, wherein the drug is an endothelia receptor antagonist or an analogue or derivative thereof.
67. The composition of claim 1, wherein the drug is a peroxisome proliferators-activated receptor agonist or an analogue or derivative thereof.
68. The composition of claim 1, wherein the drug is an estrogen receptor agent or an analogue or derivative thereof.
69. The composition of claim 1, wherein the drug is somatostatin or an analogue or derivative thereof.
70. The composition of claim 1, wherein the drug is a JNK
Kinase inhibitor or an analogue or derivative thereof.
Kinase inhibitor or an analogue or derivative thereof.
71. The composition of claim 1, wherein the drug is a melanocortin or an analogue or derivative thereof.
72. The composition of claim 1, wherein the drug is a raf kinase inhibitor or analogue or derivative thereof.
73. The composition of claim 1, wherein the drug is a lysylhydroxylase inhibitor or an analogue or derivative thereof.
74. The composition of claim 1, wherein the drug is an IKK 1/2 inhibitor or an analogue or derivative thereof.
75. The composition of claim 1, further comprising an anti-inflammatory agent, an antithrombotic agent, an antibiotic, or a combination thereof.
76. The composition of claim 1, wherein the drug further comprises a polymer.
77. The polymer of claim 76, wherein the polymer is a polymer or copolymer comprising one or more of the residue units of the monomers, lactic acid, glycolic acid, D-lactide, L-lactide, D,L-lactide, glycolide, .epsilon.-caprolactone, trimethylene carbonate, 1,4-dioxane-2-one or 1,5-dioxepan-2one,
78. The polymer of claim 77, wherein the polymer is a block copolymers of the for A-B, A-B-A or B-A-B where A is a poly(alkylene oxide) and B is a degradable polyester.
79. The poly(alkylene oxide) in claim 78, wherein the poly(alkylene oxide) is poly(ethylene glycol), poly(propylene glycol), copolymers of ethylene oxide and propylene oxide or mono alkyl ethers thereof
80. The composition of claim 76, wherein the polymer is in the form of a microsphere.
81. The composition of claim 76, wherein the polymer is in the form of a nanosphere.
82. The composition of claim 76, wherein the polymer is in the form of a micelle.
83. The composition of claim 1, wherein the drug further comprises a non-polymeric carrier.
84. The composition of claim 1, wherein the drug is a hydrophobic drug in admixture with a secondary carrier to provide drug/carrier, the drug/carrier being in admixture with the first component to provide drug/carrier/first component, the drug/carrier/first component being suspended in an aqueous buffer solution.
85. The composition of claim 1, wherein the drug is hydrophilic.
86. The composition of claim 1, wherein the drug is a hydrophilic drug in admixture with a secondary carrier to provide drug/carrier, the drug/carrier being in admixture with the first component to provide drug/carrier/first component, the drug/carrier/first component being suspended in an aqueous buffer solution.
87. The composition of claim 1, wherein the first component is suspended in a buffer solution comprising a mixture of phosphate buffer and carbonate buffer.
88. The composition of claim 2, wherein the second component comprises a mixture of succinimidyl polyalkylene oxide and maleimidyl polyalkylene oxide.
89. A method for treating tissues, comprising the steps of:
administering to a tissue site a first component comprising at least one sulfhydryl group-containing compound in liquid medium having an alkaline pH, wherein said sulfhydryl group-containing compound is given by the formula Compound1 -(SH)m, wherein m ~; and simultaneously or subsequently administering to the tissue site a second component comprising at least one sulfhydryl reactive group-containing compound either a liquid medium having a neutral or acidic pH or in powder form, wherein said sulfhydryl reactive group-containing compound is given by the formula Compound2 -Y n, wherein Y is a sulfhydryl reactive group and wherein n ~, and wherein at least one of the first or second components is a polyalkylene oxide; and simultaneously or subsequently administering to the tissue site a drug; and allowing the sulfhydryl groups and the sulfhydryl reactive groups to react with one another to form covalent bonds therebetween to form a gel in less than one minute.
administering to a tissue site a first component comprising at least one sulfhydryl group-containing compound in liquid medium having an alkaline pH, wherein said sulfhydryl group-containing compound is given by the formula Compound1 -(SH)m, wherein m ~; and simultaneously or subsequently administering to the tissue site a second component comprising at least one sulfhydryl reactive group-containing compound either a liquid medium having a neutral or acidic pH or in powder form, wherein said sulfhydryl reactive group-containing compound is given by the formula Compound2 -Y n, wherein Y is a sulfhydryl reactive group and wherein n ~, and wherein at least one of the first or second components is a polyalkylene oxide; and simultaneously or subsequently administering to the tissue site a drug; and allowing the sulfhydryl groups and the sulfhydryl reactive groups to react with one another to form covalent bonds therebetween to form a gel in less than one minute.
90. A biocompatible gel-forming drug-delivering composition for in vivo administration with a gel time of less than one minute, comprising:
polyalkylene oxide-(SH)4 and drug in a liquid medium having a pH
of between 8 and 10.5; and polyalkylene oxide-Y4, wherein Y is succinimidyl, in a liquid medium having an acidic pH.
polyalkylene oxide-(SH)4 and drug in a liquid medium having a pH
of between 8 and 10.5; and polyalkylene oxide-Y4, wherein Y is succinimidyl, in a liquid medium having an acidic pH.
91. A biocompatible gel-forming drug-delivering composition for in vivo administration with a gel time of less than one minute, comprising:
polyalkylene oxide-(SH)12 and drug in a liquid medium having an alkaline pH; and polyalkylene oxide-Y12 in a liquid medium having an acidic pH, wherein Y is a succinimidyl or maleimidyl group.
polyalkylene oxide-(SH)12 and drug in a liquid medium having an alkaline pH; and polyalkylene oxide-Y12 in a liquid medium having an acidic pH, wherein Y is a succinimidyl or maleimidyl group.
92. A biocompatible gel-forming composition for in vivo administration, comprising:
a sulfhydryl group-containing polyalkylene oxide in a liquid medium having an acidic pH, wherein said sulfhydryl group-containing polyalkylene oxide is given by the formula Core-(SH)m, wherein m ~;
a buffer solution with an alkaline pH; and drug in admixure with the polyalkylene oxide and/or the buffer solution;
wherein the sulfhydryl groups react with one another to form covalent bonds therebetween when said components are mixed together to form a gel in less than one minute.
a sulfhydryl group-containing polyalkylene oxide in a liquid medium having an acidic pH, wherein said sulfhydryl group-containing polyalkylene oxide is given by the formula Core-(SH)m, wherein m ~;
a buffer solution with an alkaline pH; and drug in admixure with the polyalkylene oxide and/or the buffer solution;
wherein the sulfhydryl groups react with one another to form covalent bonds therebetween when said components are mixed together to form a gel in less than one minute.
93. A biocompatible gel-forming drug-delivering composition for in vivo administration, comprising:
at least one sulfhydryl group-containing compound in a liquid medium having an alkaline pH, wherein said sulfhydryl group-containing compound is given by the formula Compound -(SH)m, wherein m ~;
at least one sulfhydryl reactive group-containing compound either a liquid medium having a neutral or acidic pH or in powder form, wherein said sulfhydryl reactive group-containing compound is given by the formula Compound2 -Y n, wherein Y is a sulfhydryl reactive group and wherein n ~;
at least one drug in admixture with either or both of the at least one sulfhydryl group-containing compound and the at least one sulfhydryl reactive group-containing compound; and collagen;
wherein at least one of either the sulfhydryl group-containing compound or the sulfhydryl reactive group-containing compound is a polyalkylene oxide, and wherein the sulfhydryl groups and the sulfhydryl reactive groups are capable of reacting with one another to form covalent bonds therebetween.
at least one sulfhydryl group-containing compound in a liquid medium having an alkaline pH, wherein said sulfhydryl group-containing compound is given by the formula Compound -(SH)m, wherein m ~;
at least one sulfhydryl reactive group-containing compound either a liquid medium having a neutral or acidic pH or in powder form, wherein said sulfhydryl reactive group-containing compound is given by the formula Compound2 -Y n, wherein Y is a sulfhydryl reactive group and wherein n ~;
at least one drug in admixture with either or both of the at least one sulfhydryl group-containing compound and the at least one sulfhydryl reactive group-containing compound; and collagen;
wherein at least one of either the sulfhydryl group-containing compound or the sulfhydryl reactive group-containing compound is a polyalkylene oxide, and wherein the sulfhydryl groups and the sulfhydryl reactive groups are capable of reacting with one another to form covalent bonds therebetween.
94. The composition of claim 93, wherein m and n are each 4.
95. The composition of claim 93, wherein m and n are each 12.
96. The composition of claim 93 wherein the sulfhydryl group-containing compound is a polyalkylene oxide.
97. The composition of claim 93, wherein the sulfhydryl reactive group-containing compound is a polyalkylene oxide.
98. The composition of claim 93, wherein both the sulfhydryl group-containing compound and the sulfhydryl reactive group-containing compound are polyalkylene oxides.
99. The composition of claim 98, wherein both the sulfhydryl group-containing compound and the sulfhydryl reactive group-containing compound are polyalkylene oxides.
100. The composition of claim 93, wherein only one of the first or second components is a polyalkylene oxide.
101. The composition of claim 100, wherein one of the components is a polyalkylene oxide and the other component is a functionally activated succinimidyl or maleimidyl compound which is not a polymer.
102. The composition of claim 93, wherein the covalent bonds are thioester linkages.
103. The composition of claim 93, wherein the covalent bonds are thioether linkages.
104. The composition of claim 93, wherein the covalent bonds are sulfhydryl linkages.
105. The composition of claim 93, wherein the drug is a hydrophobic drug.
106. The composition of claim 93, wherein the drug is a hydrophobic drug in admixture with a secondary carrier to provide drug/carrier, the drug/carrier being in admixture with either or both of the at least one sulfhydryl group-containing compound and the at least one sulfhydryl reactive group-containing compound.
107. The composition of claim 93, wherein the sulfhydryl group-containing compound is suspended in a buffer solution comprising a mixture of phosphate buffer and carbonate buffer.
108. The composition of claim 93, wherein the sulfhydryl reactive group-containing compound comprises a mixture of succinimidyl polyalkylene oxide and maleimidyl polyalkylene oxide.
109. The composition of claim 93, wherein the collagen is methylated collagen.
110. A biocompatible gel-forming drug-delivering composition for in vivo administration, comprising:
(a) a first component in a liquid medium having an acidic pH
comprising:
(i) at least one sulfhydryl group-containing compound given by the formula Compound -(SH)m, wherein m ~;
(ii) at least one sulfhydryl reactive group-containing compound given by the formula Compound2 -Y n, wherein Y is a sulfhydryl reactive group and wherein n ~; and (iii) collagen; and (b) a second component comprising a buffer having a pH of between 8 and 10.5;
wherein a drug is present in admixture with either or both of the first component or the second component; and wherein at least one of either the sulfhydryl group containing compound or the sulfhydryl reactive group containing compound is a polyalkylene oxide.
(a) a first component in a liquid medium having an acidic pH
comprising:
(i) at least one sulfhydryl group-containing compound given by the formula Compound -(SH)m, wherein m ~;
(ii) at least one sulfhydryl reactive group-containing compound given by the formula Compound2 -Y n, wherein Y is a sulfhydryl reactive group and wherein n ~; and (iii) collagen; and (b) a second component comprising a buffer having a pH of between 8 and 10.5;
wherein a drug is present in admixture with either or both of the first component or the second component; and wherein at least one of either the sulfhydryl group containing compound or the sulfhydryl reactive group containing compound is a polyalkylene oxide.
111. The composition of claim 110 wherein the collagen is methylated collagen.
112. The composition of claim 110 wherein the second component is a buffer solution comprising a mixture of phosphate buffer and carbonate buffer.
113. A method for forming a drug delivery composition, comprising a) selecting a first component, a second component and a drug, wherein the first component comprises at least one sulfhydryl group-containing compound in a liquid medium having an alkaline pH, wherein said sulfhydryl group-containing compound is given by the formula Compound1 -(SH)m, wherein m ~; and the second component comprises at least one sulfhydryl reactive group-containing compound in either a liquid medium having a neutral or acidic pH or in powder form, wherein said sulfhydryl reactive group-containing compound is given by the formula Compound2 -Y n, wherein Y is a sulfhydryl reactive group and wherein n ~;
at least one of the first or second components is a polyalkylene oxide;
the sulfhydryl groups and the sulfhydryl reactive groups react with one another to form covalent bonds therebetween when said components are mixed together to form a gel in less than one minute;
b) combining the first and second components in the presence of the drug, under conditions where the first component reacts with the second component.
at least one of the first or second components is a polyalkylene oxide;
the sulfhydryl groups and the sulfhydryl reactive groups react with one another to form covalent bonds therebetween when said components are mixed together to form a gel in less than one minute;
b) combining the first and second components in the presence of the drug, under conditions where the first component reacts with the second component.
114. A product produced by the method of claim 113.
115. A method for forming a drug delivery composition, comprising a) forming an admixture of polyalkylene oxide-(SH)4 and drug in a liquid medium having a pH of between 8 and 10.5; and b) forming an admixture of polyalkylene oxide-Y4, wherein Y is succinimidyl and liquid medium, the admixture having an acidic pH.
116. The method of claim 115 further comprising combining the admixtures of steps a) and b).
117. A product produced by the method of claim 116.
118. A method for forming a biocompatible gel-forming drug-delivering composition for in vivo administration with a gel time of less than one minute, comprising:
a) preparing an admixture of polyalkylene oxide-(SH)12 and drug in a liquid medium having an alkaline pH; and b) preparing polyalkylene oxide-Y12 in a liquid medium having an acidic pH, wherein Y is a succinimidyl or maleimidyl group.
a) preparing an admixture of polyalkylene oxide-(SH)12 and drug in a liquid medium having an alkaline pH; and b) preparing polyalkylene oxide-Y12 in a liquid medium having an acidic pH, wherein Y is a succinimidyl or maleimidyl group.
119. The method of claim 118 further comprising combining a) and b).
120. The product produced by the method of claim 119.
121. A method for forming a biocompatible gel-forming composition for in vivo administration, comprising:
a) preparing a sulfhydryl group-containing polyalkylene oxide in a liquid medium having an acidic pH, wherein said sulfhydryl group-containing polyalkylene oxide is given by the formula Core-(SH)m, wherein m ~;
b) providing a buffer solution with an alkaline pH; and c) adding drug to either or both of a) and b);
wherein the sulfhydryl groups react with one another to form covalent bonds therebetween when said components are mixed together to form a gel in less than one minute.
a) preparing a sulfhydryl group-containing polyalkylene oxide in a liquid medium having an acidic pH, wherein said sulfhydryl group-containing polyalkylene oxide is given by the formula Core-(SH)m, wherein m ~;
b) providing a buffer solution with an alkaline pH; and c) adding drug to either or both of a) and b);
wherein the sulfhydryl groups react with one another to form covalent bonds therebetween when said components are mixed together to form a gel in less than one minute.
122. The method of claim 121 further comprising combining a) and b).
123. The product produced by the method of claim 122.
124. A method for forming a biocompatible gel-forming drug-delivering composition for in vivo administration, comprising:
a) providing an at least one sulfhydryl group-containing compound in a liquid medium having an alkaline pH, wherein said sulfhydryl group-containing compound is given by the formula Compound -(SH)m, wherein m ~;
b) providing an at least one sulfhydryl reactive group-containing compound either in a liquid medium having a neutral or acidic pH or in powder form, wherein said sulfhydryl reactive group-containing compound is given by the formula Compound2 -Y n, wherein Y is a sulfhydryl reactive group and wherein n ~;
c) combining a drug with either or both of the at least one sulfhydryl group-containing compound and the at least one sulfhydryl reactive group-containing compound; and d) providing collagen;
wherein at least one of either the sulfhydryl group-containing compound or the sulfhydryl reactive group-containing compound is a polyalkylene oxide; and wherein the sulfhydryl groups and the sulfhydryl reactive groups are capable of reacting with one another to form covalent bonds therebetween.
a) providing an at least one sulfhydryl group-containing compound in a liquid medium having an alkaline pH, wherein said sulfhydryl group-containing compound is given by the formula Compound -(SH)m, wherein m ~;
b) providing an at least one sulfhydryl reactive group-containing compound either in a liquid medium having a neutral or acidic pH or in powder form, wherein said sulfhydryl reactive group-containing compound is given by the formula Compound2 -Y n, wherein Y is a sulfhydryl reactive group and wherein n ~;
c) combining a drug with either or both of the at least one sulfhydryl group-containing compound and the at least one sulfhydryl reactive group-containing compound; and d) providing collagen;
wherein at least one of either the sulfhydryl group-containing compound or the sulfhydryl reactive group-containing compound is a polyalkylene oxide; and wherein the sulfhydryl groups and the sulfhydryl reactive groups are capable of reacting with one another to form covalent bonds therebetween.
125. A method for forming a biocompatible gel-forming drug-delivering composition for in vivo administration, comprising:
a) providing an at least one sulfhydryl group-containing compound in a liquid medium having an alkaline pH, wherein said sulfhydryl group-containing compound is given by the formula Compound1 -(SH)m, wherein m ~;
b) providing an at least one sulfhydryl reactive group-containing compound either in a liquid medium having a neutral or acidic pH or in powder form, wherein said sulfhydryl reactive group-containing compound is given by the formula Compound2 -Y n, wherein Y is a sulfhydryl reactive group and wherein n ~; and c) providing collagen;
wherein at least one of either the sulfhydryl group-containing compound or the sulfhydryl reactive group-containing compound is a polyalkylene oxide; and wherein the sulfhydryl groups and the sulfhydryl reactive groups are capable of reacting with one another to form covalent bonds therebetween.
a) providing an at least one sulfhydryl group-containing compound in a liquid medium having an alkaline pH, wherein said sulfhydryl group-containing compound is given by the formula Compound1 -(SH)m, wherein m ~;
b) providing an at least one sulfhydryl reactive group-containing compound either in a liquid medium having a neutral or acidic pH or in powder form, wherein said sulfhydryl reactive group-containing compound is given by the formula Compound2 -Y n, wherein Y is a sulfhydryl reactive group and wherein n ~; and c) providing collagen;
wherein at least one of either the sulfhydryl group-containing compound or the sulfhydryl reactive group-containing compound is a polyalkylene oxide; and wherein the sulfhydryl groups and the sulfhydryl reactive groups are capable of reacting with one another to form covalent bonds therebetween.
126. The product produced by the method of claim 125.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43747102P | 2002-12-30 | 2002-12-30 | |
US60/437,471 | 2002-12-30 | ||
US44087503P | 2003-01-17 | 2003-01-17 | |
US60/440,875 | 2003-01-17 | ||
PCT/US2003/041580 WO2004060346A2 (en) | 2002-12-30 | 2003-12-30 | Drug delivery from rapid gelling polymer composition |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2511521A1 true CA2511521A1 (en) | 2004-07-22 |
CA2511521C CA2511521C (en) | 2012-02-07 |
Family
ID=32717905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2511521A Expired - Fee Related CA2511521C (en) | 2002-12-30 | 2003-12-30 | Drug delivery from rapid gelling polymer composition |
Country Status (9)
Country | Link |
---|---|
US (3) | US20040225077A1 (en) |
EP (2) | EP1594459B1 (en) |
JP (2) | JP2006516548A (en) |
AT (1) | ATE457716T1 (en) |
AU (1) | AU2003300076C1 (en) |
CA (1) | CA2511521C (en) |
DE (1) | DE60331367D1 (en) |
HK (1) | HK1083067A1 (en) |
WO (1) | WO2004060346A2 (en) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006516548A (en) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | Drug delivery from rapidly gelled polymer compositions |
US7883500B2 (en) * | 2003-03-26 | 2011-02-08 | G&L Consulting, Llc | Method and system to treat and prevent myocardial infarct expansion |
JP2006523235A (en) * | 2003-03-28 | 2006-10-12 | コーザン バイオサイエンシス インコーポレイテッド | Apparatus, method and composition for preventing restenosis |
US20050148512A1 (en) * | 2003-11-10 | 2005-07-07 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
US20050208095A1 (en) * | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
CA2536188A1 (en) * | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Electrical devices and anti-scarring agents |
US8277831B2 (en) * | 2004-02-17 | 2012-10-02 | Advanced Technologies And Regenerative Medicine, Llc. | Drug-enhanced adhesion prevention |
WO2005089472A2 (en) * | 2004-03-17 | 2005-09-29 | Genzyme Corporation | Anti-adhesion spraying |
US8034796B2 (en) * | 2004-04-07 | 2011-10-11 | The University Of Georgia Research Foundation, Inc. | Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods |
EA200601648A1 (en) | 2004-04-07 | 2007-04-27 | Зе Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. | GLUCOSAMINE AND GENERAL PROCEDURES GLUCOSAMINE / ANTI-INFLAMMATORY AGENT, COMPOSITIONS AND METHODS |
US20050244367A1 (en) * | 2004-05-03 | 2005-11-03 | Ilypsa, Inc. | Phospholipase inhibitors localized in the gastrointestinal lumen |
US7201918B2 (en) * | 2004-11-16 | 2007-04-10 | Microvention, Inc. | Compositions, systems and methods for treatment of defects in blood vessels |
US7879361B2 (en) * | 2005-01-04 | 2011-02-01 | Gp Medical, Inc. | Nanoparticles for drug delivery |
US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
US20080125745A1 (en) | 2005-04-19 | 2008-05-29 | Shubhayu Basu | Methods and compositions for treating post-cardial infarction damage |
US9539410B2 (en) | 2005-04-19 | 2017-01-10 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating post-cardial infarction damage |
WO2006122414A1 (en) * | 2005-05-17 | 2006-11-23 | Matregen Corp. | Depot for sustained and controlled delivery of methotrexate |
US20070100199A1 (en) * | 2005-11-03 | 2007-05-03 | Lilip Lau | Apparatus and method of delivering biomaterial to the heart |
US20080050445A1 (en) * | 2006-04-19 | 2008-02-28 | University Of South Florida | Niosome-Hydrogel Drug Delivery |
CA2656179A1 (en) * | 2006-06-21 | 2007-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for joining non-conjoined lumens |
US7732190B2 (en) * | 2006-07-31 | 2010-06-08 | Advanced Cardiovascular Systems, Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
US9242005B1 (en) | 2006-08-21 | 2016-01-26 | Abbott Cardiovascular Systems Inc. | Pro-healing agent formulation compositions, methods and treatments |
WO2008051513A2 (en) * | 2006-10-23 | 2008-05-02 | Allan Pronovost | Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding |
US9005672B2 (en) | 2006-11-17 | 2015-04-14 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8192760B2 (en) * | 2006-12-04 | 2012-06-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating tissue using silk proteins |
WO2008076383A2 (en) | 2006-12-18 | 2008-06-26 | Med Institute Inc. | Stent graft with releasable therapeutic agent |
CA2743022C (en) | 2007-01-21 | 2012-10-09 | Hemoteq Ag | Methods for coating catheter balloons with a defined quantity of active agent |
PL2136850T3 (en) * | 2007-04-13 | 2012-07-31 | Kuros Biosurgery Ag | Polymeric tissue sealant |
US20080287633A1 (en) * | 2007-05-18 | 2008-11-20 | Drumheller Paul D | Hydrogel Materials |
US20080293910A1 (en) * | 2007-05-24 | 2008-11-27 | Tyco Healthcare Group Lp | Adhesive formulatiions |
US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
CN101338036B (en) * | 2007-07-06 | 2010-11-03 | 常州百瑞吉生物医药有限公司 | Biocompatible quick-gelatinizing hydrogels and method for preparing spray thereof |
WO2009052376A1 (en) | 2007-10-18 | 2009-04-23 | Musc Foundation For Research Development | Methods for the diagnosis of genitourinary cancer |
US8232402B2 (en) | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
AU2009234203B2 (en) | 2008-04-11 | 2014-06-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Electrospun dextran fibers and devices formed therefrom |
US10046081B2 (en) | 2008-04-11 | 2018-08-14 | The Henry M Jackson Foundation For The Advancement Of Military Medicine, Inc. | Electrospun dextran fibers and devices formed therefrom |
US20090263456A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Methods and Compositions for Reducing Preventing and Treating Adhesives |
US8956641B2 (en) * | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
US8883768B2 (en) * | 2008-04-18 | 2014-11-11 | Warsaw Orthopedic, Inc. | Fluocinolone implants to protect against undesirable bone and cartilage destruction |
US9072727B2 (en) * | 2008-04-18 | 2015-07-07 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
CA2743717A1 (en) | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
WO2010070775A1 (en) * | 2008-12-19 | 2010-06-24 | 株式会社ネクスト21 | Ultra-high strength injectable hydrogel and process for producing the same |
EP2944332B1 (en) | 2009-07-10 | 2016-08-17 | Boston Scientific Scimed, Inc. | Use of nanocrystals for a drug delivery balloon |
US10080821B2 (en) | 2009-07-17 | 2018-09-25 | Boston Scientific Scimed, Inc. | Nucleation of drug delivery balloons to provide improved crystal size and density |
CA2730598C (en) * | 2010-03-16 | 2018-03-13 | Confluent Surgical, Inc. | Modulating drug release rate by controlling the kinetics of the ph transition in hydrogels |
EP2611476B1 (en) | 2010-09-02 | 2016-08-10 | Boston Scientific Scimed, Inc. | Coating process for drug delivery balloons using heat-induced rewrap memory |
JP5886749B2 (en) * | 2010-09-02 | 2016-03-16 | 日本化薬株式会社 | Drug-block copolymer complex and method for producing medicament containing the same |
KR101255337B1 (en) * | 2010-10-04 | 2013-04-16 | 한국과학기술연구원 | Nitric oxide delivery system using thermosensitive synthetic polymers |
AU2012245517B2 (en) | 2011-04-20 | 2015-07-30 | Carbylan Therapeutics, Inc. | In-situ gel forming compositions |
EP2541547A1 (en) | 2011-06-30 | 2013-01-02 | Thomson Licensing | Method and apparatus for changing the relative positions of sound objects contained within a higher-order ambisonics representation |
US8669360B2 (en) | 2011-08-05 | 2014-03-11 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
WO2013028208A1 (en) | 2011-08-25 | 2013-02-28 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
US8936784B2 (en) * | 2011-10-17 | 2015-01-20 | Poly-Med, Inc. | Absorbable in situ gel-forming system, method of making and use thereof |
US20130096479A1 (en) * | 2011-10-18 | 2013-04-18 | St. Teresa Medical, Inc. | Method of forming hemostatic products |
US10849879B2 (en) * | 2011-10-19 | 2020-12-01 | Mercator Medsystems, Inc. | Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation |
US20130149351A1 (en) * | 2011-12-09 | 2013-06-13 | University Of Southern California | Polymer scaffolds and their use in the treatment of vision loss |
US9758671B2 (en) * | 2012-07-31 | 2017-09-12 | Matthew Becker | Strain-promoted crosslinking of PEG-based hydrogels via copper-free cycloaddition |
US10016454B2 (en) * | 2012-12-04 | 2018-07-10 | Cohera Medical, Inc. | Silane-containing moisture-curable tissue sealant |
TWI624270B (en) * | 2013-01-17 | 2018-05-21 | 財團法人工業技術研究院 | Pharmaceutical composition |
US9987391B2 (en) | 2013-03-13 | 2018-06-05 | St. Jude Medical Coordination Center Bvba | Injectable hydrogels |
CA2922991A1 (en) | 2013-11-12 | 2015-05-21 | St. Teresa Medical, Inc. | Hemostatic products |
JP2015137430A (en) * | 2014-01-20 | 2015-07-30 | 国立大学法人福井大学 | Gel fiber and nonwoven fabric thereof |
US9522114B1 (en) | 2014-03-27 | 2016-12-20 | University Of South Florida | Enhanced targeted drug delivery system via chitosan hydrogel and chlorotoxin |
WO2015159995A1 (en) * | 2014-04-17 | 2015-10-22 | 典穂 神谷 | Method for producing hydrogel, method for enveloping envelopment target, and method for releasing envelopment target |
US20170369628A1 (en) * | 2015-01-02 | 2017-12-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Biodegradable polymer |
US11260027B2 (en) | 2015-07-29 | 2022-03-01 | Musc Foundation For Research Development | Donor organ pre-treatment formulation |
US10080806B2 (en) | 2015-08-19 | 2018-09-25 | International Business Machines Corporation | Sulfur-containing polymers from hexahydrotriazine and dithiol precursors as a carrier for active agents |
US9550863B1 (en) | 2015-10-05 | 2017-01-24 | International Business Machines Corporation | Polymers from stabilized imines |
US9534084B1 (en) | 2015-11-02 | 2017-01-03 | International Business Machines Corporation | High molecular weight polythioaminals from a single monomer |
US10828387B2 (en) | 2015-11-12 | 2020-11-10 | St. Teresa Medical, Inc. | Method of sealing a durotomy |
US9862802B2 (en) | 2015-11-30 | 2018-01-09 | International Business Machines Corporation | Poly(thioaminal) probe based lithography |
US10227444B2 (en) | 2016-06-01 | 2019-03-12 | International Business Machines Corporation | Degradable polyurethanes containing thioaminal groups |
US10953128B2 (en) | 2017-11-02 | 2021-03-23 | St. Teresa Medical, Inc. | Fibrin sealant products |
WO2019152917A1 (en) | 2018-02-02 | 2019-08-08 | Galen Therapeutics Llc | Apparatus and method for protecting neurons and reducing inflammation and scarring |
AU2019238197A1 (en) * | 2018-03-20 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for cancer treatment |
WO2019195728A1 (en) * | 2018-04-06 | 2019-10-10 | University Of Notre Dame Du Lac | Refillable drug delivery by affinity homing |
CN110960507B (en) * | 2018-09-30 | 2022-03-18 | 复旦大学 | Calcium phosphate-lipid nano-drug co-delivery system composed of low-molecular-weight heparin and natural drug prodrug |
CN111467322B (en) * | 2020-04-08 | 2022-03-04 | 南方医科大学南方医院 | Synthesis method and application of VB12 targeted sildenafil nano-drug |
CN113181418B (en) * | 2021-04-09 | 2022-05-03 | 青岛大学附属医院 | Medical adhesive and preparation method thereof |
CN115068668B (en) * | 2022-06-08 | 2023-05-09 | 湖南工业大学 | Core-shell structure porous hydrogel embolism microsphere and preparation method thereof |
Family Cites Families (661)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3387001A (en) | 1964-10-19 | 1968-06-04 | Lilly Co Eli | Novel aminoacyl esters of desacetyl vincaleukoblastine |
US3619371A (en) * | 1967-07-03 | 1971-11-09 | Nat Res Dev | Production of a polymeric matrix having a biologically active substance bound thereto |
SE343210B (en) * | 1967-12-20 | 1972-03-06 | Pharmacia Ab | |
US3742955A (en) * | 1970-09-29 | 1973-07-03 | Fmc Corp | Fibrous collagen derived product having hemostatic and wound binding properties |
US3894000A (en) | 1971-01-27 | 1975-07-08 | Upjohn Co | Ara-cytidine derivatives and process of preparation |
US4066650A (en) | 1971-02-11 | 1978-01-03 | Egyud Laszlo G | Keto-aldehyde-amine addition products and method of making same |
CA955937A (en) | 1971-06-28 | 1974-10-08 | Shionogi And Co. Ltd. | Cyclic phosphamide derivatives |
US3810473A (en) * | 1972-12-04 | 1974-05-14 | Avicon Inc | Liquid-laid, non-woven, fibrous collagen derived surgical web having hemostatic and wound sealing properties |
US3876501A (en) * | 1973-05-17 | 1975-04-08 | Baxter Laboratories Inc | Binding enzymes to activated water-soluble carbohydrates |
US3991045A (en) | 1973-05-30 | 1976-11-09 | Asahi Kasei Kogyo Kabushiki Kaisha | N4 -acylarabinonucleosides |
GB1479268A (en) * | 1973-07-05 | 1977-07-13 | Beecham Group Ltd | Pharmaceutical compositions |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DE2360794C2 (en) * | 1973-12-06 | 1984-12-06 | Hoechst Ag, 6230 Frankfurt | Process for the production of peptides |
US4086417A (en) | 1974-10-15 | 1978-04-25 | Asahi Kasei Kogyo Kabushiki Kaisha | Cytidine nucleotide derivatives |
US4012390A (en) | 1974-10-16 | 1977-03-15 | Eli Lilly And Company | Vinblastinoic acid |
US3949073A (en) * | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
CH596313A5 (en) * | 1975-05-30 | 1978-03-15 | Battelle Memorial Institute | |
US4279817A (en) | 1975-05-30 | 1981-07-21 | The United States Of America As Represented By The Department Of Health & Human Services | Method for producing dimer alkaloids |
IL47468A (en) * | 1975-06-12 | 1979-05-31 | Rehovot Res Prod | Process for the cross-linking of proteins using water soluble cross-linking agents |
US4233360A (en) | 1975-10-22 | 1980-11-11 | Collagen Corporation | Non-antigenic collagen and articles of manufacture |
US4488911A (en) | 1975-10-22 | 1984-12-18 | Luck Edward E | Non-antigenic collagen and articles of manufacture |
US4057548A (en) | 1975-11-11 | 1977-11-08 | Jacek Wiecko | Process for preparing methotrexate or an N-substituted derivative thereof and/or a di (lower) alkyl ester thereof and precursor therefor |
JPS5289680A (en) | 1976-01-22 | 1977-07-27 | Mitsui Toatsu Chem Inc | Preparation of 1-(2-tetrahydrofuryl)-5-flurouracil |
US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
AT352867B (en) * | 1976-05-12 | 1979-10-10 | Battelle Institut E V | BONE REPLACEMENT, BONE COMPOUND OR PROSTHESIS ANCHORING MATERIAL AND PROCESS FOR ITS PRODUCTION |
DE2623420C2 (en) | 1976-05-25 | 1978-07-06 | Stiftung Deutsches Krebsforschungszentrum, 6900 Heidelberg | Process for the preparation of asymmetrically 13-disubstituted nitrosoureas |
GB1578348A (en) * | 1976-08-17 | 1980-11-05 | Pharmacia Ab | Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic |
US4258052A (en) | 1976-08-17 | 1981-03-24 | Yu Ruey J | Treatment of psoriasis with nicotinamide analogues |
USRE30561E (en) | 1976-12-06 | 1981-03-31 | Eli Lilly And Company | Vinca alkaloid intermediates |
JPS5395917A (en) | 1977-02-03 | 1978-08-22 | Tokyo Tanabe Co | Process for preparing nitrosourea derivative of glucopyranose |
JPS53149985A (en) | 1977-05-31 | 1978-12-27 | Asahi Chem Ind Co Ltd | Preparation of 5-fluorouracil derivatives |
US4164559A (en) * | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
SE7903361L (en) | 1978-04-20 | 1979-10-21 | Johnson Matthey Co Ltd | COMPOSITIONS CONTAINING PLATINUM |
US4404970A (en) * | 1978-05-19 | 1983-09-20 | Sawyer Philip Nicholas | Hemostatic article and methods for preparing and employing the same |
US4238480A (en) | 1978-05-19 | 1980-12-09 | Sawyer Philip Nicholas | Method for preparing an improved hemostatic agent and method of employing the same |
US4390519A (en) * | 1978-05-19 | 1983-06-28 | Sawyer Philip Nicholas | Bandage with hemostatic agent and methods for preparing and employing the same |
US4215062A (en) | 1978-05-22 | 1980-07-29 | University Of Kansas Endowment Association | Anthracycline synthesis |
US4296105A (en) | 1978-08-03 | 1981-10-20 | Institut International De Pathologie Cellulaire Et Moleculaire | Derivatives of doxorubicine, their preparation and use |
US4259242A (en) | 1978-10-10 | 1981-03-31 | Eli Lilly And Company | Method of preparing vindesine sulfate |
JPS5559173A (en) | 1978-10-27 | 1980-05-02 | Kaken Pharmaceut Co Ltd | Novel fluorouracil derivative |
US4210584A (en) | 1979-01-15 | 1980-07-01 | Eli Lilly And Company | Vindesine synthesis |
JPS6023084B2 (en) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
US4412947A (en) | 1979-09-12 | 1983-11-01 | Seton Company | Collagen sponge |
US4279812A (en) * | 1979-09-12 | 1981-07-21 | Seton Company | Process for preparing macromolecular biologically active collagen |
US4371540A (en) | 1979-09-14 | 1983-02-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroimidazoles of low toxicity and high activity as radiosensitizers of hypoxic tumor cells |
DE2943520C2 (en) * | 1979-10-27 | 1982-05-19 | Fa. Carl Freudenberg, 6940 Weinheim | Process for the production of collagen sponge for medical or cosmetic purposes |
US4639456A (en) | 1980-06-10 | 1987-01-27 | Omnichem S.A. | Vinblastin-23-oyl amino acid derivatives |
US4374414A (en) | 1980-06-26 | 1983-02-15 | Gte Automatic Electric Labs Inc. | Arbitration controller providing for access of a common resource by a duplex plurality of central processing units |
CS216992B1 (en) * | 1980-07-21 | 1982-12-31 | Miroslav Stol | Composite polymere material for the biological and medicinal utilitation and method of preparation thereof |
US4299778A (en) | 1980-07-21 | 1981-11-10 | Shell Oil Company | N'Cyclopropyl-N-(fluorophenyl)-N-hydroxyureas |
JPS5929199B2 (en) | 1980-08-25 | 1984-07-18 | 一丸フアルコス株式会社 | Method for producing fat-soluble silk peptides |
US4314380A (en) * | 1980-09-26 | 1982-02-09 | Koken Co., Ltd. | Artificial bone |
US4367239A (en) | 1980-09-29 | 1983-01-04 | Kefalas A/S | Nitrosourea derivatives, pharmaceutical compositions thereof and method of preparation |
US4301277A (en) | 1980-10-20 | 1981-11-17 | Sri International | 3-Deamino-3-(4-morpholinyl) derivatives of daunorubicin and doxorubicin |
JPS5775993A (en) | 1980-10-30 | 1982-05-12 | Tetsuo Suami | Novel nitrosourea derivative and its preparation |
JPS6041078B2 (en) | 1980-11-05 | 1985-09-13 | 日新製糖株式会社 | Genthianose nitrosourea derivatives |
US4415665A (en) | 1980-12-12 | 1983-11-15 | Pharmacia Fine Chemicals Ab | Method of covalently binding biologically active organic substances to polymeric substances |
US4314054A (en) | 1981-03-23 | 1982-02-02 | Sri International | 3'-Deamino-3'-(4-methoxy-1-piperidinyl) derivatives of daunorubicin and doxorubicin |
US4494547A (en) | 1981-03-30 | 1985-01-22 | North Carolina Central University | 2H-isoindolediones, their synthesis and use as radiosensitizers |
US4414147A (en) | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
US4375432A (en) | 1981-05-12 | 1983-03-01 | Eli Lilly And Company | Method of preparing vincristine |
JPS57206622A (en) | 1981-06-10 | 1982-12-18 | Ajinomoto Co Inc | Blood substitute |
US4451568A (en) * | 1981-07-13 | 1984-05-29 | Battelle Memorial Institute | Composition for binding bioactive substances |
US4357274A (en) | 1981-08-06 | 1982-11-02 | Intermedicat Gmbh | Process for the manufacture of sclero protein transplants with increased biological stability |
US4415628A (en) | 1981-10-26 | 1983-11-15 | Seton Company | Moisture vapor permeable sheet materials |
JPS5896026A (en) * | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | Novel urokinase derivative, its preparation and thrombolytic agent containing the same |
US4424208A (en) * | 1982-01-11 | 1984-01-03 | Collagen Corporation | Collagen implant material and method for augmenting soft tissue |
US4462992A (en) | 1982-02-08 | 1984-07-31 | Research Corporation | Nitroimidazole radiosensitizers for hypoxic tumor cells and compositions thereof |
US4582640A (en) * | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
US4578067A (en) * | 1982-04-12 | 1986-03-25 | Alcon (Puerto Rico) Inc. | Hemostatic-adhesive, collagen dressing for severed biological surfaces |
JPS58180162A (en) | 1982-04-19 | 1983-10-21 | 株式会社高研 | Anti-thrombosis medical material |
US4544516A (en) * | 1982-07-28 | 1985-10-01 | Battelle Development Corporation | Collagen orientation |
US4737544A (en) * | 1982-08-12 | 1988-04-12 | Biospecific Technologies, Inc. | Biospecific polymers |
US4973493A (en) | 1982-09-29 | 1990-11-27 | Bio-Metric Systems, Inc. | Method of improving the biocompatibility of solid surfaces |
US4585859A (en) | 1983-05-24 | 1986-04-29 | Sri International | Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin |
JPS59219300A (en) | 1983-05-27 | 1984-12-10 | Nisshin Seito Kk | Sucrose nitrosourea derivative |
JPS6028936A (en) * | 1983-07-27 | 1985-02-14 | Koken:Kk | Atherocollagen aqueous solution and its preparation |
US4563351A (en) * | 1983-08-01 | 1986-01-07 | Forsyth Dental Infirmary For Children | Self-gelling therapeutic compositions for topical application |
US4902791A (en) | 1983-08-30 | 1990-02-20 | Sanofi S.A. | Nitrosourea derivatives, process for their preparation and medicaments containing them |
US4490529A (en) | 1983-09-06 | 1984-12-25 | Dana-Farber Cancer Institute, Inc. | Cysteic acid and homocysteic acid analogues of methotrexate and aminopterin |
US4894364A (en) | 1983-10-26 | 1990-01-16 | Greer Sheldon B | Method and materials for sensitizing neoplastic tissue to radiation |
US4515637A (en) * | 1983-11-16 | 1985-05-07 | Seton Company | Collagen-thrombin compositions |
US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
CA1295796C (en) * | 1984-03-27 | 1992-02-18 | Conrad Whyne | Biodegradable matrix and methods for producing same |
JPS6110511A (en) | 1984-06-26 | 1986-01-18 | Sumitomo Chem Co Ltd | Radiosensitizer for hypoxic cell |
US4789663A (en) | 1984-07-06 | 1988-12-06 | Collagen Corporation | Methods of bone repair using collagen |
US4681091A (en) | 1984-08-03 | 1987-07-21 | Picker Donald H | Combination modality cancer therapy |
JPS6145765A (en) * | 1984-08-07 | 1986-03-05 | 宇部興産株式会社 | Blood vessel prosthesis and its production |
US4553974A (en) | 1984-08-14 | 1985-11-19 | Mayo Foundation | Treatment of collagenous tissue with glutaraldehyde and aminodiphosphonate calcification inhibitor |
US4687820A (en) * | 1984-08-22 | 1987-08-18 | Cuno Incorporated | Modified polypeptide supports |
US4557764A (en) | 1984-09-05 | 1985-12-10 | Collagen Corporation | Process for preparing malleable collagen and the product thereof |
US4563350A (en) * | 1984-10-24 | 1986-01-07 | Collagen Corporation | Inductive collagen based bone repair preparations |
US4588831A (en) | 1984-11-09 | 1986-05-13 | Natec | Platinum complex compounds of substituted 5,8-dihydroxyl-1,4-naphthoquinone, and process for their production and use |
GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
US4600533A (en) * | 1984-12-24 | 1986-07-15 | Collagen Corporation | Collagen membranes for medical use |
SU1261253A1 (en) | 1984-12-27 | 1990-10-07 | Отделение Института химической физики АН СССР | Oxoammonium derivatives of nitrosourea displaying antitumor activity, and method of producing same |
US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
JPS61167616A (en) | 1985-01-22 | 1986-07-29 | Adeka Argus Chem Co Ltd | Radiation-sensitizing agent |
US4841045A (en) | 1985-03-12 | 1989-06-20 | University Of Vermont & State Agricultural College | Synthesis of vinblastine and vincristine type compounds |
US4642117A (en) * | 1985-03-22 | 1987-02-10 | Collagen Corporation | Mechanically sheared collagen implant material and method |
CA1260391A (en) * | 1985-03-28 | 1989-09-26 | Karl A. Piez | Xenogeneic collagen/mineral preparations in bone repair |
US5032617A (en) | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
US5215738A (en) | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
FR2582651B1 (en) | 1985-06-03 | 1987-08-28 | Pf Medicament | PROCESS FOR THE PREPARATION OF VINCRISTINE |
DE3521684A1 (en) * | 1985-06-18 | 1986-12-18 | Dr. Müller-Lierheim KG, Biologische Laboratorien, 8033 Planegg | METHOD FOR COATING POLYMERS |
DE3675588D1 (en) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
JPS6230768A (en) | 1985-08-01 | 1987-02-09 | Taisho Pharmaceut Co Ltd | Imidazole derivative |
JPS6230777A (en) | 1985-08-01 | 1987-02-09 | Taisho Pharmaceut Co Ltd | Imidazole derivative |
JPH0720864B2 (en) | 1985-08-15 | 1995-03-08 | 旭電化工業株式会社 | Radiosensitizer |
JPH0723308B2 (en) | 1985-12-12 | 1995-03-15 | 旭電化工業株式会社 | Radiosensitizer |
US4851513A (en) * | 1985-09-06 | 1989-07-25 | Minnesota Mining And Manufacturing Company | Viscoelastic collagen solution for opthalmic use and method of preparation |
SU1336489A1 (en) | 1985-10-24 | 1990-02-15 | Отделение Института химической физики АН СССР | Method of producing nitroxyl derivatives of nitrozo urea |
JPH0717518B2 (en) | 1985-11-28 | 1995-03-01 | 湧永製薬株式会社 | Antitumor action regulator |
EP0232693A3 (en) | 1985-12-16 | 1988-04-06 | La Region Wallonne | Conjugates of vinblastine and its derivatives, process for their preparation and pharmaceutical compositions containing them |
EP0250571B1 (en) | 1986-01-06 | 1991-05-22 | The University Of Melbourne | Precipitation of collagen in tactoid form |
US4774227A (en) * | 1986-02-14 | 1988-09-27 | Collagen Corporation | Collagen compositions for bone repair containing autogeneic marrow |
US4983580A (en) * | 1986-04-04 | 1991-01-08 | Allergan, Inc. | Methods and materials for use in corneal wound healing |
US4745180A (en) * | 1986-06-27 | 1988-05-17 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using heparin fragments |
US4841085A (en) | 1986-06-30 | 1989-06-20 | Board Of Regents, University Of Texas System | Aldophosphamides |
US4877864A (en) | 1987-03-26 | 1989-10-31 | Genetics Institute, Inc. | Osteoinductive factors |
US6432919B1 (en) | 1986-07-01 | 2002-08-13 | Genetics Institute, Inc. | Bone morphogenetic protein-3 and compositions |
US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
FR2601676B1 (en) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | PROCESS FOR THE PREPARATION OF TAXOL AND DESACETYL-10 TAXOL |
FR2601675B1 (en) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US5004606A (en) | 1986-09-24 | 1991-04-02 | Hybritech Incorporated | Non-covalent antibody-anthracycline immunocomplexes |
US5624925A (en) | 1986-09-25 | 1997-04-29 | Sri International | 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents |
US5175287A (en) | 1986-09-25 | 1992-12-29 | S R I International | Process for preparing 1,2,4-benzotriazine oxides |
US4979959A (en) | 1986-10-17 | 1990-12-25 | Bio-Metric Systems, Inc. | Biocompatible coating for solid surfaces |
JPS63170375A (en) | 1987-01-07 | 1988-07-14 | Pola Chem Ind Inc | Heterocyclic compound derivative, its production and radiosensitizer containing said derivative as active component |
GB8701381D0 (en) | 1987-01-22 | 1987-02-25 | Erba Farmitalia | Antitumor agent |
US5047528A (en) | 1987-01-22 | 1991-09-10 | University Of Bristish Columbia | Process of synthesis of vinblastine and vincristine |
FR2611203B1 (en) | 1987-02-20 | 1989-06-09 | Sturtz Georges | GEM-DIPHOSPHONIC ANALOGS OF AMETHOPTERIN (METHOTREXATE) AND DEAZA-N-10 AMETHOPTERINE DERIVATIVES. THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US5034320A (en) | 1987-03-31 | 1991-07-23 | Allelix, Inc. | Vinblastine synthesis |
US4921963A (en) | 1987-04-13 | 1990-05-01 | British Columbia Cancer Foundation | Platinum complexes with one radiosensitizing ligand |
DE3887194T2 (en) | 1987-05-08 | 1994-07-28 | Sankyo Co | Antitumor platinum complexes, their production and their therapeutic use. |
JPS63310873A (en) | 1987-06-09 | 1988-12-19 | Taiho Yakuhin Kogyo Kk | 4,5-dinitroimidazole derivative |
CA1329206C (en) | 1987-06-10 | 1994-05-03 | Tsutomu Kagiya | Fluorine-containing nitroazole derivatives and radiosensitizer comprising the same |
US5304654A (en) | 1987-06-10 | 1994-04-19 | Yasunori Nishijima | Fluorine-containing nitroimidazole compounds |
JP2602887B2 (en) | 1987-06-10 | 1997-04-23 | 京都大学長 | New fluorine-containing 3-nitro-1,2,4-triazole and radiosensitizer containing the same |
US4797397A (en) | 1987-07-31 | 1989-01-10 | Warner-Lambert Company | 2-nitroimidazole derivatives useful as radiosensitizers for hypoxic tumor cells |
US5532220A (en) | 1987-08-31 | 1996-07-02 | The Regents Of The University Of California | Genetic mechanisms of tumor suppression |
JPH01139596A (en) | 1987-11-25 | 1989-06-01 | Pola Chem Ind Inc | Heterocyclic compound derivative, production thereof and radiosensitizer, antiviral and anticancer agent containing said derivative as active ingredient |
US4996152A (en) | 1987-12-04 | 1991-02-26 | The United States Of America, As Represented By The Secretary Of Agriculture | Avian herpesvirus amplicon as a eucaryotic expression vector |
US5364622A (en) | 1987-12-04 | 1994-11-15 | Dr. Karl Thomae Gmbh | Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel |
US4950699A (en) * | 1988-01-11 | 1990-08-21 | Genetic Laboratories, Inc. | Wound dressing incorporating collagen in adhesive layer |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US5192316A (en) * | 1988-02-16 | 1993-03-09 | Allergan, Inc. | Ocular device |
US5024742A (en) * | 1988-02-24 | 1991-06-18 | Cedars-Sinai Medical Center | Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers |
US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
US5591624A (en) | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
US6133029A (en) | 1988-03-21 | 2000-10-17 | Chiron Corporation | Replication defective viral vectors for infecting human cells |
US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US4923876A (en) | 1988-04-18 | 1990-05-08 | Cetus Corporation | Vinca alkaloid pharmaceutical compositions |
US5290552A (en) * | 1988-05-02 | 1994-03-01 | Matrix Pharmaceutical, Inc./Project Hear | Surgical adhesive material |
US5190929A (en) | 1988-05-25 | 1993-03-02 | Research Corporation Technologies, Inc. | Cyclophosphamide analogs useful as anti-tumor agents |
US4908356A (en) | 1988-05-25 | 1990-03-13 | Research Corporation Technologies, Inc. | Aldophosphamide derivatives useful as antitumor agents |
US4950483A (en) * | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
US5167960A (en) | 1988-08-03 | 1992-12-01 | New England Deaconess Hospital Corporation | Hirudin-coated biocompatible substance |
US4906460A (en) | 1988-08-05 | 1990-03-06 | Sorenco | Additive for hair treatment compositions |
US5665583A (en) | 1988-08-12 | 1997-09-09 | Arch Dev Corp | Methods and materials relating to IMPDH and GMP production |
US5066658A (en) | 1988-11-10 | 1991-11-19 | Ortho Pharmaceutical Corporation | Substituted hydroxyureas |
US5936035A (en) * | 1988-11-21 | 1999-08-10 | Cohesion Technologies, Inc. | Biocompatible adhesive compositions |
US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US5304595A (en) | 1988-11-21 | 1994-04-19 | Collagen Corporation | Collagen-polymer conjugates |
US5306500A (en) * | 1988-11-21 | 1994-04-26 | Collagen Corporation | Method of augmenting tissue with collagen-polymer conjugates |
US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
US5475052A (en) | 1988-11-21 | 1995-12-12 | Collagen Corporation | Collagen-synthetic polymer matrices prepared using a multiple step reaction |
US5264214A (en) | 1988-11-21 | 1993-11-23 | Collagen Corporation | Composition for bone repair |
US5109112A (en) | 1989-01-19 | 1992-04-28 | Merck & Co., Inc. | FK-506 cytosolic binding protein |
JPH04503306A (en) | 1989-02-01 | 1992-06-18 | ザ・ジェネラル・ホスピタル・コーポレーション | Herpes simplex virus type 1 expression vector |
US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
DE69033982T2 (en) | 1989-03-21 | 2002-10-24 | Us Health | Matrix metalloproteinase inhibitor peptides |
US5641764A (en) | 1989-03-31 | 1997-06-24 | Peter Maccallum Institute | Halogenated DNA ligand radiosensitizers for cancer therapy |
ATE122723T1 (en) | 1989-03-31 | 1995-06-15 | Canji Inc | RETINOBLASTOMA GENE PRODUCT ANTIBODIES AND USES THEREOF. |
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5324844A (en) * | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5141747A (en) * | 1989-05-23 | 1992-08-25 | Minnesota Mining And Manufacturing Company | Denatured collagen membrane |
US5200411A (en) | 1989-06-14 | 1993-04-06 | Sandoz, Ltd. | Heteroatoms-containing tricyclic compounds |
DE3924424A1 (en) | 1989-07-24 | 1991-01-31 | Boehringer Mannheim Gmbh | NUCLEOSIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICINAL PRODUCT AND THEIR USE IN THE SEQUENCING OF NUCLEIC ACID |
US5100885A (en) | 1989-08-01 | 1992-03-31 | Johnson Matthey, Inc. | Copper radiosensitizers |
NZ234718A (en) * | 1989-08-11 | 1992-05-26 | Saint Gobain Isover | Decomposable glass fibres |
US5166149A (en) | 1989-09-08 | 1992-11-24 | Chemex Pharmaceuticals, Inc. | Methotrexate compositions and methods of treatment using same |
ES2094136T3 (en) | 1989-12-19 | 1997-01-16 | Pharmacia Spa | CHIRAL INTERMEDIARIES OF 1,5-DIYODO-2-METOXI OR BENCILOXI. |
JP2626727B2 (en) | 1990-01-26 | 1997-07-02 | ポーラ化成工業株式会社 | 2-Nitroimidazole derivative, process for producing the same and radiosensitizer containing the same as an active ingredient |
US5201764A (en) * | 1990-02-28 | 1993-04-13 | Autogenesis Technologies, Inc. | Biologically compatible collagenous reaction product and articles useful as medical implants produced therefrom |
US5104957A (en) | 1990-02-28 | 1992-04-14 | Autogenesis Technologies, Inc. | Biologically compatible collagenous reaction product and articles useful as medical implants produced therefrom |
US5989894A (en) | 1990-04-20 | 1999-11-23 | University Of Wyoming | Isolated DNA coding for spider silk protein, a replicable vector and a transformed cell containing the DNA |
US5219564A (en) * | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
US5688678A (en) | 1990-05-16 | 1997-11-18 | Genetics Institute, Inc. | DNA encoding and methods for producing BMP-8 proteins |
US5594158A (en) | 1990-06-22 | 1997-01-14 | The Board Of Regents Of The University Of Nebraska | Processes for producing doxorubicin, daunomycinone, and derivatives of doxorubicin |
US5210030A (en) | 1990-06-25 | 1993-05-11 | Merck & Co., Inc. | Process for selectively acylating immunomycin |
EP0536215A4 (en) | 1990-06-29 | 1993-07-21 | The Regents Of The University Of Michigan | Neurofibromatosis gene |
US5147652A (en) | 1990-07-03 | 1992-09-15 | Cell Research Corporation | Autobiotics and their use in eliminating nonself cells in vivo |
US5209776A (en) * | 1990-07-27 | 1993-05-11 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
US5059699A (en) | 1990-08-28 | 1991-10-22 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
US5278324A (en) | 1990-08-28 | 1994-01-11 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
SE466754B (en) * | 1990-09-13 | 1992-03-30 | Berol Nobel Ab | COVALENT BINDING POLYMERS TO HYDROPHILIC SURFACES |
PT98990A (en) | 1990-09-19 | 1992-08-31 | American Home Prod | PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN |
US5817491A (en) | 1990-09-21 | 1998-10-06 | The Regents Of The University Of California | VSV G pseusdotyped retroviral vectors |
US5198421A (en) | 1991-04-26 | 1993-03-30 | Merck & Co., Inc. | Phosphorylated cyclic lipopeptide |
US5626863A (en) * | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5380536A (en) | 1990-10-15 | 1995-01-10 | The Board Of Regents, The University Of Texas System | Biocompatible microcapsules |
US5410016A (en) * | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5169754A (en) | 1990-10-31 | 1992-12-08 | Coulter Corporation | Biodegradable particle coatings having a protein covalently immobilized by means of a crosslinking agent and processes for making same |
US5892112A (en) | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
US5183900A (en) | 1990-11-21 | 1993-02-02 | Galardy Richard E | Matrix metalloprotease inhibitors |
US5189178A (en) | 1990-11-21 | 1993-02-23 | Galardy Richard E | Matrix metalloprotease inhibitors |
US5268384A (en) | 1990-11-21 | 1993-12-07 | Galardy Richard E | Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors |
US5239078A (en) | 1990-11-21 | 1993-08-24 | Glycomed Incorporated | Matrix metalloprotease inhibitors |
WO1993013663A1 (en) | 1992-01-17 | 1993-07-22 | Abbott Laboratories | Method of directing biosynthesis of specific polyketides |
US5116756A (en) | 1991-01-28 | 1992-05-26 | Merck & Co., Inc. | Process for producing FK-506 |
US5219895A (en) * | 1991-01-29 | 1993-06-15 | Autogenesis Technologies, Inc. | Collagen-based adhesives and sealants and methods of preparation and use thereof |
US5294715A (en) | 1991-02-01 | 1994-03-15 | University Of Pittsburgh | Acridine-intercalator based hypoxia selective cytotoxins |
US5156613A (en) * | 1991-02-13 | 1992-10-20 | Interface Biomedical Laboratories Corp. | Collagen welding rod material for use in tissue welding |
GB9103430D0 (en) | 1991-02-19 | 1991-04-03 | Smithkline Beecham Plc | Novel compound |
TW197439B (en) | 1991-04-04 | 1993-01-01 | Ueno Pharmaceutics Applic Res Co Ltd | |
US5147877A (en) | 1991-04-18 | 1992-09-15 | Merck & Co. Inc. | Semi-synthetic immunosuppressive macrolides |
US5091389A (en) | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
US5093338A (en) | 1991-04-23 | 1992-03-03 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
US5140018A (en) | 1991-05-07 | 1992-08-18 | Abbott Laboratories | 1,3,2-benzodithiazole-1-oxide compounds |
US5889169A (en) | 1991-05-16 | 1999-03-30 | Cold Spring Harbor Laboratory | Cell cycle regulatory protein p16 gene |
DK0592562T3 (en) | 1991-06-25 | 1999-08-30 | Genetics Inst | BMP-9 compositions |
US5225403A (en) | 1991-06-25 | 1993-07-06 | Merck & Co., Inc. | C-21 hydroxylated FK-506 antagonist |
CA2071160A1 (en) | 1991-07-31 | 1993-02-01 | Vittorio Farina | Asymmetric synthesis of taxol side chain |
US5256657A (en) | 1991-08-19 | 1993-10-26 | Sterling Winthrop, Inc. | Succinamide derivative matrix-metalloprotease inhibitors |
US5534632A (en) | 1991-09-05 | 1996-07-09 | Abbott Laboratories | Macrocyclic carbamate immunomodulators |
EP0642516B1 (en) | 1991-09-05 | 2002-06-05 | Abbott Laboratories | Macrocyclic immunomodulators |
US5561137A (en) | 1991-09-05 | 1996-10-01 | Abbott Laboratories | Thio-heterocyclic macrolactam immunomodulators |
US5541193A (en) | 1991-09-05 | 1996-07-30 | Abbott Laboratories | Heterocycle-containing macrocyclic immunomodulators |
US5563172A (en) | 1991-09-05 | 1996-10-08 | Abbott Laboratories | Macrocyclic amide and urea immunomodulators |
US5604234A (en) | 1991-09-05 | 1997-02-18 | Abbott Laboratories | Substituted thiol macrolactam immunomodulators |
US5208241A (en) | 1991-09-09 | 1993-05-04 | Merck & Co., Inc. | N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity |
US5252732A (en) | 1991-09-09 | 1993-10-12 | Merck & Co., Inc. | D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity |
US5247076A (en) | 1991-09-09 | 1993-09-21 | Merck & Co., Inc. | Imidazolidyl macrolides having immunosuppressive activity |
US5283253A (en) | 1991-09-23 | 1994-02-01 | Florida State University | Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them |
US5350866A (en) | 1991-09-23 | 1994-09-27 | Bristol-Myers Squibb Company | 10-desacetoxytaxol derivatives |
AU3124793A (en) | 1991-10-29 | 1993-06-07 | Clover Consolidated, Limited | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
FR2683529B1 (en) | 1991-11-12 | 1994-02-04 | Bretagne Occidentale Universite | PHARMACEUTICAL COMPOUNDS GEM-DIPHOSPHONATES ANALOGUE OF CIS-PLATINUM. |
US5164399A (en) | 1991-11-18 | 1992-11-17 | American Home Products Corporation | Rapamycin pyrazoles |
AU3140093A (en) | 1991-11-22 | 1993-06-15 | University Of Mississippi, The | Synthesis and optical resolution of the taxol side chain and related compounds |
NZ240785A (en) | 1991-11-28 | 1995-08-28 | Cancer Res Campaign Tech | Substituted nitro aniline derivatives and medicaments |
GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
US5221625A (en) | 1992-01-10 | 1993-06-22 | Merck & Co., Inc. | Cyclcic FR-900520 microbial biotransformation agent |
US5272171A (en) | 1992-02-13 | 1993-12-21 | Bristol-Myers Squibb Company | Phosphonooxy and carbonate derivatives of taxol |
WO1993018043A1 (en) | 1992-03-05 | 1993-09-16 | American Home Products Corporation | Novel rapamycin 42-sulfonates and 42-(n-carboalkoxy)sulfamates useful as immunosuppressive agents |
US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
US5324634A (en) | 1992-03-31 | 1994-06-28 | The Research Foundation Of State University Of New York | Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer |
US5440056A (en) | 1992-04-17 | 1995-08-08 | Abbott Laboratories | 9-deoxotaxane compounds |
WO1993021942A2 (en) | 1992-05-01 | 1993-11-11 | British Biotech Pharmaceuticals Limited | Use of mmp inhibitors |
AU4242993A (en) | 1992-05-21 | 1993-12-13 | Penn State Research Foundation, The | Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
WO1993024476A1 (en) | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
WO1993025533A1 (en) | 1992-06-05 | 1993-12-23 | Abbott Laboratories | Methods and reagents for the determination of immunosuppressive agents |
US5248796A (en) | 1992-06-18 | 1993-09-28 | Bristol-Myers Squibb Company | Taxol derivatives |
GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
US5274137A (en) | 1992-06-23 | 1993-12-28 | Nicolaou K C | Intermediates for preparation of taxols |
US5294637A (en) | 1992-07-01 | 1994-03-15 | Bristol-Myers Squibb Company | Fluoro taxols |
US5254580A (en) | 1993-01-19 | 1993-10-19 | Bristol-Myers Squibb Company | 7,8-cyclopropataxanes |
WO1994001483A1 (en) | 1992-07-02 | 1994-01-20 | Collagen Corporation | Biocompatible polymer conjugates |
US5385606A (en) | 1992-07-06 | 1995-01-31 | Kowanko; Nicholas | Adhesive composition and method |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
ZA935110B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
GB9215665D0 (en) | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
US5324644A (en) | 1992-07-28 | 1994-06-28 | Merck & Co., Inc. | Process for producing immunosuppressant agent |
MX9304399A (en) | 1992-07-31 | 1994-02-28 | Warner Lambert Co | NOVEL PROCESS TO PREPARE [[2-BROMOETHYL) -AMINO] METHYL] -2-NITRO-1H-IMIDAZOL-1-ETHANOL CHIRAL AND RELATED COMPOUNDS. |
US5514379A (en) * | 1992-08-07 | 1996-05-07 | The General Hospital Corporation | Hydrogel compositions and methods of use |
MX9304868A (en) | 1992-08-13 | 1994-05-31 | American Home Prod | 27-HYDROXYRAPAMICINE, DERIVED FROM THE SAME AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT. |
US5202448A (en) | 1992-08-14 | 1993-04-13 | Napro Biotherapeutics, Inc. | Processes of converting taxanes into baccatin III |
US5614549A (en) * | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
WO1994005282A1 (en) | 1992-09-04 | 1994-03-17 | The Scripps Research Institute | Water soluble taxol derivatives |
CA2100808A1 (en) | 1992-10-01 | 1994-04-02 | Vittorio Farina | Deoxy paclitaxels |
FR2696461B1 (en) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | New derivatives of taxol analogs, their preparation and compositions containing them. |
FR2696463B1 (en) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Process for obtaining 10-deacetyl baccatin III. |
FR2696464B1 (en) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | New esterification process for baccatin III and 10-deacetyl baccatin III. |
FR2696462B1 (en) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Process for obtaining 10-deacetyl baccatin III. |
US5318895A (en) | 1992-10-05 | 1994-06-07 | Merck & Co., Inc. | Aspergillus niger mutants |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5411984A (en) | 1992-10-16 | 1995-05-02 | Virginia Tech Intellectual Properties, Inc. | Water soluble analogs and prodrugs of taxol |
US5552156A (en) | 1992-10-23 | 1996-09-03 | Ohio State University | Liposomal and micellular stabilization of camptothecin drugs |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
ZA938349B (en) | 1992-11-10 | 1994-08-01 | Smithkline Beecham Corp | Rapamycin derivatives. |
WO1994011533A1 (en) | 1992-11-12 | 1994-05-26 | The Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services | METHODS FOR DETERMINING THE PRESENCE OF FUNCTIONAL p53 IN MAMMALIAN CELLS |
GB9223904D0 (en) | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
US5661033A (en) | 1992-11-25 | 1997-08-26 | The Board Of Trustees Of The Leland Stanford Junior University | Gene transfer using herpes virus vectors as a tool for neuroprotection |
US5380751A (en) | 1992-12-04 | 1995-01-10 | Bristol-Myers Squibb Company | 6,7-modified paclitaxels |
US5279949A (en) | 1992-12-07 | 1994-01-18 | Board Of Trustees Operating Michigan State University | Process for the isolation and purification of taxol and taxanes from Taxus spp |
US5298643A (en) * | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
JPH06203767A (en) | 1992-12-28 | 1994-07-22 | Matsushita Electron Corp | Deflection yoke |
US5349001A (en) * | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
GB9302016D0 (en) | 1993-02-02 | 1993-03-17 | Sandoz Ltd | Compounds |
US5321095A (en) * | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
US6284513B1 (en) | 1993-02-03 | 2001-09-04 | Warner-Lambert Company | Process for the production of stromelysin catalytic domain protein |
GB9302569D0 (en) | 1993-02-10 | 1993-03-24 | Smithkline Beecham Plc | Novel compound |
US5310901A (en) | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives |
US5310903A (en) | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
WO1994020089A1 (en) | 1993-03-09 | 1994-09-15 | Enzon, Inc. | Taxol-based compositions with enhanced bioactivity |
US5457194A (en) | 1993-03-17 | 1995-10-10 | Abbott Laboratories | Substituted aliphatic amine-containing macrocyclic immunomodulators |
WO1994021253A1 (en) | 1993-03-17 | 1994-09-29 | Abbott Laboratories | Substituted aliphatic amine-containing macrocyclic immunomodulators |
US5594006A (en) | 1993-03-18 | 1997-01-14 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives as matrix metalloproteinases inhibitors |
US5382582A (en) | 1993-03-26 | 1995-01-17 | Chan; Carcy L. | Methotrexate analogs and methods of using same |
GB9307956D0 (en) | 1993-04-17 | 1993-06-02 | Walls Alan J | Hydroxamic acid derivatives |
ES2295093T3 (en) | 1993-04-23 | 2008-04-16 | Wyeth | CONJUGATES AND RAPAMYCIN ANTIBODIES. |
US5412092A (en) | 1993-04-23 | 1995-05-02 | Bristol-Myers Squibb Company | N-substituted 2-azetidinones |
US5306727A (en) | 1993-04-30 | 1994-04-26 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
US5380897A (en) | 1993-05-25 | 1995-01-10 | Hoeschele; James D. | Tri(platinum) complexes |
FR2705686B1 (en) | 1993-05-28 | 1995-08-18 | Transgene Sa | New defective adenoviruses and corresponding complementation lines. |
US5549904A (en) * | 1993-06-03 | 1996-08-27 | Orthogene, Inc. | Biological adhesive composition and method of promoting adhesion between tissue surfaces |
DE69434447T2 (en) | 1993-06-07 | 2006-05-18 | Vical, Inc., San Diego | PLASMIDE FOR GENE THERAPY |
JPH08511426A (en) | 1993-06-15 | 1996-12-03 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | Novel recombinantly produced spider silk analog |
JPH07107058B2 (en) | 1993-06-22 | 1995-11-15 | 旭電化工業株式会社 | Nitrotriazole compound |
US6140087A (en) | 1993-06-24 | 2000-10-31 | Advec, Inc. | Adenovirus vectors for gene therapy |
US6080569A (en) | 1993-06-24 | 2000-06-27 | Merck & Co., Inc. | Adenovirus vectors generated from helper viruses and helper-dependent vectors |
DE69421183T2 (en) | 1993-07-20 | 2000-01-20 | Pfizer | HETEROARYL CYLOALKENYL HYDROXY UREA |
GB9315914D0 (en) | 1993-07-31 | 1993-09-15 | Smithkline Beecham Plc | Novel compound |
US5773428A (en) | 1993-08-05 | 1998-06-30 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
US6013792A (en) | 1993-08-05 | 2000-01-11 | Syntex (U.S.A.), Inc. | Matrix metalloprotease inhibitors |
US5387680A (en) | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
GB9318612D0 (en) | 1993-09-08 | 1993-10-27 | Sandoz Ltd | An assay |
US5409915A (en) | 1993-09-14 | 1995-04-25 | The University Of Vermont And State Agricultural College | Bis-platinum (IV) complexes as chemotherapeutic agents |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5470834A (en) | 1993-10-06 | 1995-11-28 | Florida State University | Sulfoximine and suldodiimine matrix metalloproteinase inhibitors |
US5455262A (en) | 1993-10-06 | 1995-10-03 | Florida State University | Mercaptosulfide metalloproteinase inhibitors |
US5650442A (en) | 1993-10-08 | 1997-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers |
US6210939B1 (en) | 1993-10-25 | 2001-04-03 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5605976A (en) * | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
US6037472A (en) | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
GB9323165D0 (en) | 1993-11-10 | 1994-01-05 | Chiros Ltd | Compounds |
WO1995013375A1 (en) | 1993-11-10 | 1995-05-18 | The Johns Hopkins University | Tumor suppressor waf1 |
US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
EP0729471A1 (en) | 1993-11-19 | 1996-09-04 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
WO1995015328A1 (en) | 1993-11-30 | 1995-06-08 | Abbott Laboratories | Macrocyclic immunomodulators with novel cyclohexyl ring replacements |
US5484799A (en) | 1993-12-09 | 1996-01-16 | Abbott Laboratories | Antifungal dorrigocin derivatives |
CN1046944C (en) | 1993-12-17 | 1999-12-01 | 山道士有限公司 | Rapamycin derivatives useful as immunosuppressants |
GB9401129D0 (en) | 1994-01-21 | 1994-03-16 | British Bio Technology | Hydroxamic acid derivatives as metalloproteinase inhibitors |
JP3827324B2 (en) | 1994-01-22 | 2006-09-27 | ブリテッシュ バイオテック ファーマシューティカルズ リミテッド | Metalloproteinase inhibitor |
US5457182A (en) | 1994-02-15 | 1995-10-10 | Merck & Co., Inc. | FK-506 cytosolic binding protein, FKBP12.6 |
US5444072A (en) | 1994-02-18 | 1995-08-22 | Syntex (U.S.A.) Inc. | 6-substituted mycophenolic acid and derivatives |
US5362735A (en) | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
US5514716A (en) | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
FR2716893B1 (en) | 1994-03-03 | 1996-04-12 | Rhone Poulenc Rorer Sa | Recombinant viruses, their preparation and their therapeutic use. |
US5395850A (en) | 1994-03-10 | 1995-03-07 | Bristol-Myers Squibb Company | 6,7-epoxy paclitaxels |
GB9405076D0 (en) | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
FI951367A (en) | 1994-03-28 | 1995-09-29 | Japan Energy Corp | Purine derivatives and suppressants for infectious diseases |
CA2187626C (en) | 1994-04-13 | 2009-11-03 | Michael G. Kaplitt | Aav-mediated delivery of dna to cells of the nervous system |
US6013517A (en) | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
US6140099A (en) | 1994-05-20 | 2000-10-31 | The Trustees Of The University Of Pennsylvania | Method of delaying fetal membrane rupture by inhibiting matrix metalloproteinase-9 activity |
US5641636A (en) | 1994-05-20 | 1997-06-24 | University Of Pennsylvania | Method of predicting fetal membrane rupture based on matrix metalloproteinase-9 activity |
GB9411088D0 (en) | 1994-06-03 | 1994-07-27 | Hoffmann La Roche | Hydroxylamine derivatives |
ATE336587T1 (en) | 1994-06-10 | 2006-09-15 | Genvec Inc | ADENOVIRUS VECTOR SYSTEMS AND CELL LINES |
DE69511089T2 (en) | 1994-06-22 | 1999-12-16 | British Biotech Pharm | METALLOPROTEINASE INHIBITORS |
US5622866A (en) | 1994-06-23 | 1997-04-22 | Merck & Co., Inc. | Expression cassettes useful in construction of integrative and replicative expression vectors for Streptomyces |
US5583114A (en) | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
DE69513837T2 (en) | 1994-07-27 | 2000-05-18 | Novartis Ag | Cyclopeptolides |
GB9416897D0 (en) | 1994-08-20 | 1994-10-12 | British Biotech Pharm | Metalloproteinase inhibitors |
CZ288436B6 (en) | 1994-10-05 | 2001-06-13 | Darwin Discovery Ltd | Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
CA2203809C (en) | 1994-10-28 | 2008-06-03 | James M. Wilson | Recombinant adenovirus and methods of use thereof |
AR002945A1 (en) | 1994-11-15 | 1998-05-27 | Bayer Corp | ACIDOS 4-BIARILBUTIRICO OR 5-BIARILPENTANOICO SUBSTITUTED AND ITS DERIVATIVES AS INHIBITORS OF MATRIX METALOPROTEASES, COMPOSITION CONTAINING THEM, AND METHODS FOR THE PREPARATION OF SUCH COMPOUNDS |
US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
EP0713707A1 (en) | 1994-11-23 | 1996-05-29 | Collagen Corporation | In situ crosslinkable, injectable collagen composition for tissue augmention |
GB9423914D0 (en) | 1994-11-26 | 1995-01-11 | British Biotech Pharm | Polyether derivatives as metalloproteinase inhibitors |
US5532265A (en) | 1994-11-30 | 1996-07-02 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of central nervous system inflammatory disease with matrix metalloprotease inhibitors |
US5639746A (en) | 1994-12-29 | 1997-06-17 | The Procter & Gamble Company | Hydroxamic acid-containing inhibitors of matrix metalloproteases |
US5602142A (en) | 1994-12-21 | 1997-02-11 | Evanston Hospital Corporation | DNA-affinic hypoxia selective cytotoxins |
JP2902318B2 (en) | 1994-12-28 | 1999-06-07 | 呉羽化学工業株式会社 | Esculetin derivatives, their production method and matrix metalloprotease inhibitors |
US6033847A (en) | 1995-02-06 | 2000-03-07 | St. Jude Children's Research Hospital | InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and CDK6, and uses thereof |
US5672598A (en) | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
BR9607977A (en) | 1995-03-23 | 1998-01-13 | Univ Texas | Photoinitiated and redox preparation systems for improved gel adhesion to substrates |
AU711702B2 (en) | 1995-03-23 | 1999-10-21 | Cambridge University Technical Services Limited | Vectors for gene delivery |
US5900245A (en) * | 1996-03-22 | 1999-05-04 | Focal, Inc. | Compliant tissue sealants |
US6025480A (en) | 1995-04-03 | 2000-02-15 | Sloan-Kettering Institute For Cancer Research | Isolated nucleic acid molecules encoding P57KIP2 |
US5691381A (en) | 1995-04-18 | 1997-11-25 | The Dupont Merck Pharmaceutical Company | Hydroxamic and carbocyclic acids as metalloprotease inhibitors |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
WO1996033968A1 (en) | 1995-04-25 | 1996-10-31 | Fuji Yakuhin Kogyo Kabushiki Kaisha | Highly water-soluble metalloproteinase inhibitor |
JPH11504646A (en) | 1995-05-10 | 1999-04-27 | カイロサイエンス・リミテッド | Peptide compounds inhibiting the release of metalloproteases and TNF and their therapeutic use |
WO1996035712A1 (en) | 1995-05-10 | 1996-11-14 | Chiroscience Limited | Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use |
CA2217850A1 (en) | 1995-05-10 | 1996-11-14 | Chirotech Technology Limited | Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use |
US5698706A (en) | 1995-05-10 | 1997-12-16 | Chiroscience Limited | Heterocyclic amides and methods of use |
GB9509631D0 (en) | 1995-05-12 | 1995-07-05 | Sandoz Ltd | Antifungal combination |
JP3133642B2 (en) | 1995-05-19 | 2001-02-13 | 花王株式会社 | Hair cosmetics |
US5665764A (en) | 1995-06-02 | 1997-09-09 | Warner-Lambert Company | Tricyclic inhibitors of matrix metalloproteinases |
US5627206A (en) | 1995-06-02 | 1997-05-06 | Warner-Lambert Company | Tricyclic inhibitor of matrix metalloproteinases |
US5886022A (en) | 1995-06-05 | 1999-03-23 | Bayer Corporation | Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors |
US6040183A (en) | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
US5677282A (en) | 1995-06-07 | 1997-10-14 | Proscript, Inc. | Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
AU712193B2 (en) | 1995-06-09 | 1999-10-28 | Novartis Ag | Rapamycin derivatives |
DE69633565T3 (en) | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRES, FOR USE IN GENE THERAPY |
US5917090A (en) | 1995-06-30 | 1999-06-29 | British Biotech Pharmaceuticals Ltd. | Matrix metalloproteinase inhibitors |
GB9514867D0 (en) | 1995-07-20 | 1995-09-20 | British Biotech Pharm | Metalloproteinase inhibitors |
KR980009238A (en) | 1995-07-28 | 1998-04-30 | 우에노 도시오 | Sulfonyl amino acid derivative |
AUPN477695A0 (en) | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
WO1997010502A1 (en) | 1995-09-15 | 1997-03-20 | Merck & Co., Inc. | A high throughput assay using fusion proteins |
US5723313A (en) | 1995-09-27 | 1998-03-03 | St. Jude Children's Research Hospital | ARF-p19, a novel regulator of the mammalian cell cycle |
US5684152A (en) | 1995-09-28 | 1997-11-04 | Merck & Co., Inc. | Preparation of carboxyalkyl derivatives as inhibitors of matrix metalloproteinases |
US5665777A (en) | 1995-11-14 | 1997-09-09 | Abbott Laboratories | Biphenyl hydroxamate inhibitors of matrix metalloproteinases |
PL326700A1 (en) | 1995-11-17 | 1998-10-26 | Warner Lambert Co | Sulphonamide-based inhibitors of intercellular substance metaloproteinases |
US5830727A (en) | 1995-11-18 | 1998-11-03 | Human Gene Therapy Research Institute | Herpes simplex virus amplicon mini-vector gene transfer system |
AU711804B2 (en) | 1995-11-23 | 1999-10-21 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
US5843903A (en) | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
US6117633A (en) | 1995-12-08 | 2000-09-12 | University Technologies International Inc. | DNA sequence encoding the tumor suppressor gene ING1 |
US6458889B1 (en) | 1995-12-18 | 2002-10-01 | Cohesion Technologies, Inc. | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
JP4193917B2 (en) | 1995-12-18 | 2008-12-10 | アンジオデバイス インターナショナル ゲーエムベーハー | Crosslinked polymer composition and method of use thereof |
US5752974A (en) * | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
ATE225343T1 (en) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | MATRIX METALLOPROTEASE INHIBITORS |
CZ287868B6 (en) | 1995-12-22 | 2001-02-14 | Warner Lambert Co | Aromatic keto-acids and their derivatives functioning as inhibitors of matrix metalloproteinases |
DE19548624A1 (en) | 1995-12-23 | 1997-06-26 | Boehringer Mannheim Gmbh | New barbituric acid derivatives, processes for their preparation and medicaments containing these compounds |
DK0871439T3 (en) | 1996-01-02 | 2004-08-02 | Aventis Pharma Inc | Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US5744349A (en) | 1996-03-05 | 1998-04-28 | Washington University | DNA sequences encoding human Myt1 kinase |
GB9607120D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
GB9607119D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
GB9607249D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
AU2725797A (en) | 1996-04-10 | 1997-10-29 | Sloan-Kettering Institute For Cancer Research | Methods for enhancing animal growth and cell proliferation by elimination of functional p27kip1 |
HUP0004421A3 (en) | 1996-04-23 | 2002-10-28 | Vertex Pharmaceuticals Inc Cam | Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme |
US6128582A (en) | 1996-04-30 | 2000-10-03 | Vertex Pharmaceuticals Incorporated | Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
US5863915A (en) | 1996-05-15 | 1999-01-26 | Bayer Corporation | Substituted 4-arylbutyric acid derivatives as matrix metalloprotease |
US5925637A (en) | 1997-05-15 | 1999-07-20 | Bayer Corporation | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids |
US5932577A (en) | 1996-05-15 | 1999-08-03 | Bayer Corporation | Substituted oxobutyric acids as matrix metalloprotease inhibitors |
US5968795A (en) | 1996-05-15 | 1999-10-19 | Bayer Corporation | Biaryl acetylenes as inhibitors of matrix metalloproteases |
EP0914450A1 (en) | 1996-05-20 | 1999-05-12 | Signal Pharmaceuticals, Inc. | MITOGEN-ACTIVATED PROTEIN KINASE p38-2 AND METHODS OF USE THEREFOR |
WO1997048688A1 (en) | 1996-06-21 | 1997-12-24 | Pharmacia & Upjohn Company | Thiadiazole amide mmp inhibitors |
US5852213A (en) | 1996-07-10 | 1998-12-22 | American Cyanamid Company | Mercaptoketones and mercaptoalcohols and a process for their preparation |
US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
HUP9903014A3 (en) | 1996-07-18 | 2000-08-28 | Pfizer | Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same |
ATE233552T1 (en) | 1996-07-22 | 2003-03-15 | Monsanto Co | THIOL-SULFONES AS METALLOPROTEINASE INHIBITORS |
DK0968182T3 (en) | 1996-08-07 | 2004-08-16 | Darwin Discovery Ltd | Hydroxamic and carboxylic acid derivatives with MMP and TNF inhibitory activity |
IT1284876B1 (en) | 1996-08-07 | 1998-05-22 | Applied Research Systems | HCG AS A COLLAGENASE INHIBITOR |
US6566384B1 (en) | 1996-08-07 | 2003-05-20 | Darwin Discovery Ltd. | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
GB9616643D0 (en) | 1996-08-08 | 1996-09-25 | Chiroscience Ltd | Compounds |
US6020366A (en) | 1996-08-16 | 2000-02-01 | Warner-Lambert Company | Butyric acid matrix metalloproteinase inhibitors |
JP3539736B2 (en) | 1996-08-28 | 2004-07-07 | ザ プロクター アンド ギャンブル カンパニー | Phosphinamides as substrate metalloprotease inhibitors |
US6624177B1 (en) | 1996-09-04 | 2003-09-23 | Warner-Lambert Company | Matrix metalloproteinase inhibitors and their therapeutic uses |
WO1998009940A1 (en) | 1996-09-04 | 1998-03-12 | Warner-Lambert Company | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
KR20000068415A (en) | 1996-09-04 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Compounds for and a Method of Inhibiting Matrix Metalloproteinase |
US6022948A (en) | 1996-09-17 | 2000-02-08 | Washington University | Method of cell surface activation and inhibition |
WO1998012243A1 (en) | 1996-09-23 | 1998-03-26 | Focal, Inc. | Polymerizable biodegradable polymers including carbonate or dioxanone linkages |
EA001460B1 (en) | 1996-09-27 | 2001-04-23 | Фармация Энд Апджон Компани | beta-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS |
US6228869B1 (en) | 1996-10-16 | 2001-05-08 | American Cyanamid Company | Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US5929097A (en) | 1996-10-16 | 1999-07-27 | American Cyanamid Company | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US5977408A (en) | 1996-10-16 | 1999-11-02 | American Cyanamid Company | Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US5962481A (en) | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
GB9621814D0 (en) | 1996-10-19 | 1996-12-11 | British Biotech Pharm | Metalloproteinase inhibitors |
AU4812697A (en) | 1996-10-22 | 1998-05-15 | Pharmacia & Upjohn Company | Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors |
US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
MY117687A (en) | 1996-10-31 | 2004-07-31 | Bayer Corp | Substituted 4-biphenyl-4-hydroxybutric acid derivatives as matrix metalloprotease inhibitors |
JPH10130217A (en) | 1996-11-01 | 1998-05-19 | Kotobuki Seiyaku Kk | Carboxylic acid, its derivative, its production and pharmaceutical composition containing the acid |
US5965441A (en) | 1996-11-13 | 1999-10-12 | The General Hospital Coporation | HSV/AAV hybrid amplicon vectors |
CN1244215B (en) | 1996-11-20 | 2010-11-03 | 荷兰克鲁塞尔公司 | Improved method for the production and purification of adenoviral vectors |
NZ334897A (en) | 1996-12-09 | 2001-02-23 | Warner Lambert Co | Medicaments for treating and preventing heart failure and ventricular dilatation |
ZA9711121B (en) | 1996-12-13 | 1998-06-23 | Handelman Joseph H | Reduction of hair growth. |
DE69727695T2 (en) | 1996-12-17 | 2005-02-10 | Warner-Lambert Co. Llc | USE OF MATRIX METALLOPROTEINASE INHIBITORS TO PROMOTE WOUND HEALING |
WO1998027069A1 (en) | 1996-12-17 | 1998-06-25 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine compounds as inhibitors of mmp or tnf |
US5985911A (en) | 1997-01-07 | 1999-11-16 | Abbott Laboratories | C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion |
US5952320A (en) | 1997-01-07 | 1999-09-14 | Abbott Laboratories | Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion |
US6153436A (en) | 1997-01-10 | 2000-11-28 | The Board Of Trustees Of The University Of Arkansas | Method of gene delivery using wildtype adeno associated viral (AAV) vectors with insertions |
AU720615B2 (en) | 1997-01-17 | 2000-06-08 | Pharmacia & Upjohn Company | Bis-sulfonomides hydroxamic acids as MMP inhibitors |
GB9702088D0 (en) | 1997-01-31 | 1997-03-19 | Pharmacia & Upjohn Spa | Matrix metalloproteinase inhibitors |
AU6144498A (en) | 1997-02-06 | 1998-08-26 | Osiris Therapeutics, Inc. | P21cip1 or p27kip1 effects on the regulation of differentiation of human mesenchymal stem cells |
CA2281944C (en) | 1997-02-25 | 2007-05-15 | The Regents Of The University Of Michigan | Methods and compositions for preventing and treating chronological aging in human skin |
US6172057B1 (en) | 1997-02-27 | 2001-01-09 | American Cyanamid Company | N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
US6197791B1 (en) | 1997-02-27 | 2001-03-06 | American Cyanamid Company | N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
WO1998039316A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | N-hydroxy 4-sulfonyl butanamide compounds |
US6087359A (en) | 1997-03-04 | 2000-07-11 | Getman; Daniel P. | Thioaryl sulfonamide hydroxamic acid compounds |
EP0977745B1 (en) | 1997-03-04 | 2004-12-01 | Pharmacia Corporation | Thioaryl sulfonamide hydroxamic acid compounds |
BR9808214A (en) | 1997-03-04 | 2000-05-16 | Monsanto Co | N-hydroxy 4-sulfonyl butanamide compounds |
US6638952B1 (en) | 1997-03-04 | 2003-10-28 | Pharmacia Corporation | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
US6362183B1 (en) | 1997-03-04 | 2002-03-26 | G. D. Searle & Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
EP0966465B1 (en) | 1997-03-14 | 2003-07-09 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
US5932600A (en) | 1997-03-14 | 1999-08-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US20020111495A1 (en) | 1997-04-04 | 2002-08-15 | Pfizer Inc. | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes |
GB9707333D0 (en) | 1997-04-11 | 1997-05-28 | British Biotech Pharm | Metalloproteinase inhibitors |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US5756545A (en) | 1997-04-21 | 1998-05-26 | Warner-Lambert Company | Biphenysulfonamide matrix metal alloproteinase inhibitors |
FR2762315B1 (en) | 1997-04-22 | 1999-05-28 | Logeais Labor Jacques | AMINO ACID DERIVATIVES INHIBITOR OF EXTRACELLULAR MATRIX METALLOPROTEASES AND TNF ALPHA RELEASE |
WO1998051810A1 (en) | 1997-05-13 | 1998-11-19 | University Of North Carolina At Chapel Hill | Lentivirus-based gene transfer vectors |
US5804581A (en) | 1997-05-15 | 1998-09-08 | Bayer Corporation | Inhibition of matrix metalloproteases by substituted phenalkyl compounds |
US5932763A (en) | 1997-05-15 | 1999-08-03 | Bayer Corporation | Inhibition of matrix metalloproteases by 2-(ω-arolalkyl)-4-biaryl-4-oxobutyric acids |
GB9710490D0 (en) | 1997-05-21 | 1997-07-16 | British Biotech Pharm | Metalloproteinase inhibitors |
TWI234467B (en) | 1997-06-04 | 2005-06-21 | Univ Michigan | Composition for inhibiting photoaging of skin |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
US6300514B1 (en) | 1997-06-25 | 2001-10-09 | Ono Pharmaceutical Co., Ltd. | Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient |
GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
AU8479498A (en) | 1997-07-08 | 1999-02-08 | Cold Spring Harbor Laboratory | Dual specificity phosphatase and methods of use |
US6482827B1 (en) | 1997-07-10 | 2002-11-19 | Pharmacia & Upjohn S.P.A. | Matrix metalloproteinase inhibitors |
GB9714971D0 (en) | 1997-07-16 | 1997-09-24 | Cancer Res Campaign Tech | Assays,therapeutic methods and means |
GB9715030D0 (en) | 1997-07-18 | 1997-09-24 | British Biotech Pharm | Metalloproteinase inhibitors |
US6221646B1 (en) | 1997-07-31 | 2001-04-24 | Chiron Corporation | Materials and methods for simplified AAV production |
US6162241A (en) | 1997-08-06 | 2000-12-19 | Focal, Inc. | Hemostatic tissue sealants |
US6294573B1 (en) | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
US6235786B1 (en) | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
US5854382A (en) * | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
EP0897908A1 (en) | 1997-08-19 | 1999-02-24 | Roche Diagnostics GmbH | 3-Aryl-succinamido-hydroxamic acids, process for their preparation and medicaments containing them |
US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
US6448058B1 (en) | 1997-09-12 | 2002-09-10 | Versicor, Inc. | Methods for solid phase synthesis of mercapto compounds and derivatives, combinatorial libraries thereof and compositions obtained thereby |
GB9719426D0 (en) | 1997-09-13 | 1997-11-12 | Johnson Matthey Plc | Novel process |
US5997895A (en) | 1997-09-16 | 1999-12-07 | Integra Lifesciences Corporation | Dural/meningeal repair product using collagen matrix |
WO2000000600A2 (en) | 1997-09-22 | 2000-01-06 | Chang Lung Ji | Lentiviral vectors, comprising modified major donor splice sites and major packaging signals |
ES2245042T3 (en) | 1997-09-24 | 2005-12-16 | The Regents Of The University Of California | VECTORS OF NON-PRIMATE LENTIVIRUS AND PACKAGING SYSTEMS. |
US6080874A (en) | 1997-09-25 | 2000-06-27 | Abbott Laboratories | Synthesis and isolation of N-(aryl or heteroaryl)-alkyl-N-hydroxyurea |
JPH11106775A (en) | 1997-10-03 | 1999-04-20 | Taiho Kogyo Co Ltd | Solid lubricating film composition and plain bering material prepared therefrom |
US6399612B1 (en) | 1997-10-06 | 2002-06-04 | Warner-Lambert Company | Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
CN1282319A (en) | 1997-10-09 | 2001-01-31 | 小野药品工业株式会社 | Aminobutanoic acid derivatives |
BR9812944A (en) | 1997-10-20 | 2000-08-08 | Hoffmann La Roche | Bicyclic kinase inhibitors |
WO1999024464A1 (en) | 1997-11-10 | 1999-05-20 | Dana-Farber Cancer Institute, Inc | Glycosylated modified primate lentivirus envelope polypeptides |
AU746158B2 (en) | 1997-11-12 | 2002-04-18 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
US6187924B1 (en) | 1997-11-12 | 2001-02-13 | Darwin Discovery, Ltd. | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
US6063786A (en) | 1997-11-12 | 2000-05-16 | Darwin Discovery, Ltd. | Heterocyclic compounds having MMP and TNF inhibitory activity |
IL135586A0 (en) | 1997-11-21 | 2001-05-20 | Upjohn Co | α-HYDROXY, -AMINO, AND HALO DERIVATIVES OF β-SULFONYL HYDROXAMIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
KR20010033062A (en) | 1997-12-12 | 2001-04-25 | 루이기 낼다이니 | Therapeutic use of lentiviral vectors |
US6335156B1 (en) | 1997-12-18 | 2002-01-01 | The Johns Hopkins University School Of Medicine | 14-3-3σ arrests the cell cycle |
AU751701B2 (en) | 1997-12-23 | 2002-08-22 | Warner-Lambert Company | Ace inhibitor-MMP inhibitor combinations |
US5994099A (en) | 1997-12-31 | 1999-11-30 | The University Of Wyoming | Extremely elastic spider silk protein and DNA coding therefor |
ES2209244T3 (en) | 1998-01-09 | 2004-06-16 | Pfizer Inc. | INHIBITORS OF THE METALOPROTEASES OF THE MATRIX. |
US6071903A (en) | 1998-01-27 | 2000-06-06 | American Cyanamid Company | 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
GB9804504D0 (en) | 1998-03-03 | 1998-04-29 | Leo Pharm Prod Ltd | Matrix metalloproteinase inhibitors |
US6169103B1 (en) | 1998-03-03 | 2001-01-02 | Warner-Lambert | Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
US6037361A (en) | 1998-03-09 | 2000-03-14 | Warner-Lambert Company | Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
IL131217A0 (en) * | 1998-03-10 | 2001-01-28 | Napro Biotherapeutics Inc | Novel methods and compositions for delivery of taxanes |
US6100032A (en) | 1998-03-13 | 2000-08-08 | Johns Hopkins University | Human Smad3 and Smad4 are sequence-specific transcription activators |
FI980604A0 (en) | 1998-03-18 | 1998-03-18 | Univ Helsinki Licensing | New matrix metalloprotein inhibitors and regulators |
JP2002507427A (en) | 1998-03-27 | 2002-03-12 | ザ スクリップス リサーチ インスティテュート | Kinase Weel fusion protein composition, nucleotide sequence, expression system and use thereof |
US6277061B1 (en) | 1998-03-31 | 2001-08-21 | The Research Foundation Of State University Of New York | Method of inhibiting membrane-type matrix metalloproteinase |
WO1999051754A1 (en) | 1998-04-02 | 1999-10-14 | Dana-Farber Cancer Institute, Inc. | Infectious pseudotyped lentiviral vectors lacking matrix protein and uses thereof |
DK0952148T3 (en) | 1998-04-10 | 2004-09-20 | Pfizer Prod Inc | Cyclobutylaryloxyarylsulfonylaminohydroxamic acid derivatives |
GT199900044A (en) | 1998-04-10 | 2000-09-14 | PROCEDURES FOR PREPARING PHENOXYPHENYL SULFONYL HALIDES. | |
PA8469601A1 (en) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | PROCEDURE FOR RENTING STERICALLY IMPAIRED SULFONAMIDES |
AU3665199A (en) | 1998-04-29 | 1999-11-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
JPH11313675A (en) | 1998-04-30 | 1999-11-16 | Hoechst Marion Roussel Kk | Human bmp-7 promotor and screening of bone-related substance using the same |
US20020156114A1 (en) | 1998-05-05 | 2002-10-24 | Goldstein David Michael | Pyrazole derivatives - p38 MAP kinase inhibitors |
US6316466B1 (en) | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
US6376527B1 (en) | 1998-05-05 | 2002-04-23 | Syntex (U.S.A.) Llc | Pyrazole derivatives-p38 map kinase inhibitors |
EP1077971A1 (en) | 1998-05-14 | 2001-02-28 | G.D. SEARLE & CO. | 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
US6288063B1 (en) | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
US6168807B1 (en) | 1998-07-23 | 2001-01-02 | Les Laboratoires Aeterna Inc. | Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof |
OA11589A (en) | 1998-07-30 | 2004-07-30 | Warner Lambert Co | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases. |
AU4229499A (en) | 1998-07-30 | 2000-02-21 | Warner-Lambert Company | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases |
US6117869A (en) | 1998-08-04 | 2000-09-12 | Warner-Lambert Company | Compounds for and methods of inhibiting matrix metalloproteinases |
US6514534B1 (en) | 1998-08-14 | 2003-02-04 | Incept Llc | Methods for forming regional tissue adherent barriers and drug delivery systems |
WO2000012477A1 (en) | 1998-08-29 | 2000-03-09 | British Biotech Pharmaceuticals Limited | Hydroxamic acid derivatives as proteinase inhibitors |
US6509337B1 (en) | 1998-09-17 | 2003-01-21 | Pfizer Inc. | Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors |
CA2344412A1 (en) | 1998-09-21 | 2000-03-30 | Takeda Chemical Industries, Ltd. | Thiol compound, their production and use |
WO2000024725A1 (en) | 1998-10-26 | 2000-05-04 | Vertex Pharmaceuticals Incorporated | Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase |
US6596747B2 (en) | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
US6420403B1 (en) | 1998-10-29 | 2002-07-16 | Edwin J. Iwanowicz | Inhibitors of IMPDH enzyme |
AU764479B2 (en) | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
EP1127054A4 (en) | 1998-10-29 | 2006-11-02 | Bristol Myers Squibb Co | Novel inhibitors of impdh enzyme |
US6210922B1 (en) | 1998-11-30 | 2001-04-03 | National Research Council Of Canada | Serum free production of recombinant proteins and adenoviral vectors |
AU2476200A (en) | 1998-12-04 | 2000-06-19 | Immusol, Inc | Ribozyme therapy for the treatment and/or prevention of restenosis |
WO2000033764A1 (en) | 1998-12-04 | 2000-06-15 | Pathak Chandrashekhar P | Biocompatible crosslinked polymers |
US6328229B1 (en) | 1998-12-18 | 2001-12-11 | Cohesion Technologies, Inc. | Low volume mixing spray head for mixing and dispensing of two reactive fluid components |
US6288261B1 (en) | 1998-12-18 | 2001-09-11 | Abbott Laboratories | Inhibitors of matrix metalloproteinases |
US6352976B1 (en) | 1998-12-31 | 2002-03-05 | Aventis Pharmaceuticals Inc. | Selective inhibitors of MMP-12 |
US6262080B1 (en) | 1998-12-31 | 2001-07-17 | Avantis Pharmaceuticals Inc. | 3-(thio-substitutedamido)-lactams useful as inhibitors of matrix metalloproteinase |
US6544980B2 (en) | 1998-12-31 | 2003-04-08 | Aventis Pharmaceuticals Inc. | N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase |
US6486193B2 (en) | 1998-12-31 | 2002-11-26 | Aventis Pharmaceuticals Inc. | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases |
US6329550B1 (en) | 1998-12-31 | 2001-12-11 | Aventis Pharmaceuticals Inc. | Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase |
US6294539B1 (en) | 1999-01-19 | 2001-09-25 | Advanced Syntech, Llc | Heterocyclic hydroxamic acid derivatives as MMP inhibitors |
EP1147085B1 (en) | 1999-01-27 | 2005-11-16 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors |
JP2002536373A (en) | 1999-02-08 | 2002-10-29 | ジー・ディー・サール・アンド・カンパニー | Sulfamethhydroxamic acid metalloprotease inhibitors |
GB9903598D0 (en) | 1999-02-18 | 1999-04-07 | Univ Manchester | Connective tissue healing |
US6514979B1 (en) | 1999-03-03 | 2003-02-04 | University Of Maryland Biotechnology Institute | Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor |
EE200100492A (en) | 1999-03-19 | 2002-12-16 | Vertex Pharmaceuticals Incorporated | IMPDH inhibitors |
EP1165546A2 (en) | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase |
JP2002541138A (en) | 1999-04-02 | 2002-12-03 | デュポン ファーマシューティカルズ カンパニー | Novel amide derivatives as inhibitors of matrix metalloproteases, TNF-α and aggrecanase |
WO2000059865A1 (en) | 1999-04-06 | 2000-10-12 | Ono Pharmaceutical Co., Ltd. | 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient |
CO5170501A1 (en) | 1999-04-14 | 2002-06-27 | Novartis Ag | USEFUL REPLACED BLUES FOR THE TREATMENT OF DISEASES MEDIATED BY TNFa eIL-1 AND DISEASES OF THE OSEO METABOLISM |
US6312725B1 (en) * | 1999-04-16 | 2001-11-06 | Cohesion Technologies, Inc. | Rapid gelling biocompatible polymer composition |
CN1347411A (en) | 1999-04-19 | 2002-05-01 | 盐野义制药株式会社 | Sulfonamide derivs. having oxadiazole rings |
WO2000066759A1 (en) | 1999-04-29 | 2000-11-09 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US6287588B1 (en) * | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
US6509361B1 (en) | 1999-05-12 | 2003-01-21 | Pharmacia Corporation | 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors |
US6583299B1 (en) | 1999-05-20 | 2003-06-24 | G.D. Searle & Co. | α-amino-β-sulfonyl hydroxamic acid compounds |
EP1181939B1 (en) | 1999-05-24 | 2006-05-31 | Shionogi & Co., Ltd. | Method for evaluating in vivo matrix metalloproteinase inhibitory activity |
AU5031200A (en) | 1999-05-28 | 2000-12-18 | Vertex Pharmaceuticals Incorporated | Method for preparing 5-substituted oxazoles |
US6511993B1 (en) | 1999-06-03 | 2003-01-28 | Kevin Neil Dack | Metalloprotease inhibitors |
JP3362778B2 (en) | 1999-06-03 | 2003-01-07 | 独立行政法人農業生物資源研究所 | Method for producing ultrafine crystalline silk powder |
US6294694B1 (en) | 1999-06-04 | 2001-09-25 | Wisconsin Alumni Research Foundation | Matrix metalloproteinase inhibitors and method of using same |
MXPA02000294A (en) | 1999-06-25 | 2002-06-21 | Vertex Pharma | Prodrugs of carbamate inhibitors of impdh. |
US6541521B1 (en) | 1999-07-12 | 2003-04-01 | Warner-Lambert Company | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
KR20010010393A (en) * | 1999-07-20 | 2001-02-05 | 김윤 | Biodegradable Block Copolymer of Hydrophobic and Hydrophilic Polymers, and Composition for Drug Delivery Comprising Same |
AU6866700A (en) | 1999-09-01 | 2001-03-26 | Ajinomoto Co., Inc. | Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof |
IL138686A0 (en) | 1999-10-01 | 2001-10-31 | Pfizer Prod Inc | α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS |
SE9904177D0 (en) | 1999-11-18 | 1999-11-18 | Astra Ab | Novel compounds |
GB9929979D0 (en) | 1999-12-17 | 2000-02-09 | Darwin Discovery Ltd | Hydroxamic acid derivatives |
US6380253B1 (en) | 2000-01-05 | 2002-04-30 | Efa Sciences Llc | Method of stabilizing and potentiating the action of anti-angiogenic substances |
EA005028B1 (en) | 2000-01-31 | 2004-10-28 | Пфайзер Продактс Инк. | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
US7354941B2 (en) | 2000-01-31 | 2008-04-08 | Pfizer Products Inc. | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes |
CA2398668C (en) | 2000-02-17 | 2010-06-15 | 3M Innovative Properties Company | Delivery systems using preformed biodegradable polymer compositions and methods |
US6867299B2 (en) | 2000-02-24 | 2005-03-15 | Hoffmann-La Roche Inc. | Oxamide IMPDH inhibitors |
US6465508B1 (en) | 2000-02-25 | 2002-10-15 | Wyeth | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors |
JP2003525628A (en) | 2000-03-03 | 2003-09-02 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
US6458822B2 (en) | 2000-03-13 | 2002-10-01 | Pfizer Inc. | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases |
IL151018A0 (en) | 2000-03-17 | 2003-02-12 | Bristol Myers Squibb Pharma Co | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
EP1268474A2 (en) | 2000-03-30 | 2003-01-02 | Takeda Chemical Industries, Ltd. | Substituted 1,3-thiazole compounds, their production and use |
US20020019539A1 (en) | 2000-03-31 | 2002-02-14 | Bailey Anne E. | Process for the preparation of matrix metalloproteinase inhibitors |
JP4008708B2 (en) | 2000-04-07 | 2007-11-14 | サムスン エレクトロニクス カンパニー リミテッド | Sulfonamide derivatives as inhibitors of matrix metalloproteinases |
BR0110023A (en) | 2000-04-13 | 2003-12-30 | Pharmasset Ltd | Substituted 3'-or-2 'nucleoside derivatives for treatment of hepatitis virus infections |
CA2407370A1 (en) | 2000-04-24 | 2001-11-01 | Bristol-Myers Squibb Company | Heterocycles that are inhibitors of impdh enzyme |
US6503892B2 (en) | 2000-04-26 | 2003-01-07 | New England Medical Center Hospitals Inc. | Method of using matrix metalloproteinase inhibitors in filtering blebs following glaucoma filtering surgery and in the treatment of ischemic damage to the retina and optic nerve |
CA2408921A1 (en) | 2000-05-10 | 2001-11-15 | Bristol-Myers Squibb Company | Modified inosine 5'-monophosphate dehydrogenase polypeptides and uses thereof |
US6469020B2 (en) | 2000-05-15 | 2002-10-22 | Darwin Discovery, Ltd. | Hydroxamic and carboxylic acid derivatives |
ATE277938T1 (en) | 2000-07-18 | 2004-10-15 | Leo Pharma As | MATRIX METALLOPROTEINASE INHIBITORS |
AU2001220806A1 (en) | 2000-08-22 | 2002-03-04 | Ribapharm Inc. | Improved specificity in treatment of diseases |
JP4146721B2 (en) | 2000-08-31 | 2008-09-10 | エフ.ホフマン−ラ ロシュ アーゲー | 7-Oxo-pyridopyrimidines |
SV2003000617A (en) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M |
US6455570B1 (en) | 2000-10-06 | 2002-09-24 | The Trustees Of The University Of Pennsylvania | Polypyrrolinone based inhibitors of matrix metalloproteases |
US20020151491A1 (en) | 2000-11-28 | 2002-10-17 | Jian-Dong Li | Composition and method for treating the over-production of mucin in diseases such as otitis media using an inhibitor of MUC5AC |
CA2432287A1 (en) | 2000-12-15 | 2002-09-06 | Triangle Pharmaceuticals, Inc. | Dapd combination therapy with inosine monophosphate dehydrogenase inhibitor |
DE10064997A1 (en) | 2000-12-23 | 2002-06-27 | Merck Patent Gmbh | New 1-benzoyl-3-phenyl-tetrahydropyridazine derivatives, useful for treating e.g. allergy, are selective inhibitors of phosphodiesterase IV, and new intermediates |
US6600057B2 (en) | 2000-12-29 | 2003-07-29 | Kimberly-Clark Worldwide, Inc. | Matrix metalloproteinase inhibitors |
WO2002055491A2 (en) | 2001-01-11 | 2002-07-18 | Bristol Myers Squibb Company P | 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a) |
RS50236B (en) | 2001-01-22 | 2009-07-15 | Merck & Co.Inc., | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
PL365443A1 (en) | 2001-01-31 | 2005-01-10 | Pfizer Products Inc. | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes |
CA2436535A1 (en) | 2001-01-31 | 2002-08-08 | Prizer Products Inc. | Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
WO2002060896A1 (en) | 2001-01-31 | 2002-08-08 | Pfizer Products Inc. | Ether derivatives useful as inhibitors of pde4 isozymes |
MXPA03007166A (en) | 2001-02-12 | 2003-11-18 | Hoffmann La Roche | 6-substituted pyrido-pyrimidines. |
MXPA01013172A (en) | 2001-02-14 | 2002-08-21 | Warner Lambert Co | Sulfonamide matrix metalloproteinase inhibitors. |
MXPA01013171A (en) | 2001-02-14 | 2004-05-21 | Warner Lambert Co | Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors. |
WO2002072150A2 (en) | 2001-03-13 | 2002-09-19 | Angiotech Pharmaceuticals Inc. | Micellar drug delivery vehicles and uses thereof |
AU2002338286A1 (en) | 2001-04-10 | 2002-10-28 | Leo Pharma A/S | Novel aminophenyl ketone derivatives |
MXPA03009760A (en) * | 2001-04-25 | 2005-10-05 | Eidgenoessische Technische Hoc | Drug delivery matrices to enhance wound healing. |
US20030166201A1 (en) | 2001-04-30 | 2003-09-04 | Jensen Michael C. | Selection systems for genetically modified cells |
AU2002257456A1 (en) | 2001-05-24 | 2002-12-03 | University Of Western Ontario | Control of myogenesis by modulation of p38 map kinase activity |
ES2333412T3 (en) | 2001-05-25 | 2010-02-22 | Bristol-Myers Squibb Company | HYDANTOIN DERIVATIVES AS MATRIX METALOPROTEINASE INHIBITORS. |
US20030100031A1 (en) | 2001-06-11 | 2003-05-29 | Steven Dower | Integrative assays for monitoring molecular assembly events |
US20050020482A1 (en) | 2001-06-15 | 2005-01-27 | Jennifer Phipps | Methods for modulating gap junctions |
GB0117506D0 (en) | 2001-07-18 | 2001-09-12 | Bayer Ag | Imidazopyridinones |
US6770647B2 (en) | 2001-08-17 | 2004-08-03 | Bristol-Myers Squibb Pharma Company | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
US6824769B2 (en) | 2001-08-28 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Optimal compositions and methods thereof for treating HCV infections |
DE60207273T2 (en) | 2001-08-30 | 2006-07-20 | F. Hoffmann-La Roche Ag | Aminopyrrole compounds as anti-inflammatory agents |
EP1427408A4 (en) | 2001-09-17 | 2005-10-26 | Bristol Myers Squibb Co | CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-$g(a) CONVERTING ENZYME (TACE) |
US7015217B2 (en) | 2001-10-09 | 2006-03-21 | Bristol-Myers Squibb Company | Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
WO2003035066A1 (en) | 2001-10-23 | 2003-05-01 | Celltech R & D Limited | 2-aminoquinolone derivatives for use as impdh inhibitors |
EP1463509A1 (en) | 2001-10-31 | 2004-10-06 | MERCK PATENT GmbH | Type 4 phosphodiesterase inhibitors and uses thereof |
WO2003040103A1 (en) | 2001-11-02 | 2003-05-15 | Bristol-Myers Squibb Company | β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) |
DE60213841T2 (en) | 2001-11-05 | 2007-02-15 | Merck Patent Gmbh | Hydrazono-MALONITRILE |
NZ532779A (en) | 2001-11-09 | 2008-04-30 | Intarcia Therapeutics Inc | Method for treating diseases with omega interferon |
US6936620B2 (en) | 2001-12-20 | 2005-08-30 | Bristol Myers Squibb Company | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases |
US7294624B2 (en) | 2001-12-20 | 2007-11-13 | Bristol Myers Squibb Company | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases |
WO2003053958A1 (en) | 2001-12-20 | 2003-07-03 | Celltech R & D Limited | Quinazolinedione derivatives |
TW200301698A (en) | 2001-12-21 | 2003-07-16 | Bristol Myers Squibb Co | Acridone inhibitors of IMPDH enzyme |
MXPA04007124A (en) | 2002-02-01 | 2004-10-29 | Omeros Corp | Compositions and methods for systemic inhibition of cartilage degradation. |
WO2003079986A2 (en) | 2002-03-18 | 2003-10-02 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases |
JP4611641B2 (en) | 2002-03-20 | 2011-01-12 | エラン ファーマ インターナショナル,リミティド | Nanoparticle composition of MAP kinase inhibitor |
WO2003082287A1 (en) | 2002-03-22 | 2003-10-09 | Bristol-Myers Squibb Company | Dpc 333 formulation having unique biopharmaceutical characteristics |
GB0208224D0 (en) | 2002-04-10 | 2002-05-22 | Celltech R&D Ltd | Chemical compounds |
GB0208223D0 (en) | 2002-04-10 | 2002-05-22 | Celltech R&D Ltd | Chemical compounds |
US6620813B1 (en) | 2002-06-21 | 2003-09-16 | Medinox, Inc. | Hydroxamate derivatives of non-steroidal anti-inflammatory drugs |
AU2003295432A1 (en) | 2002-11-12 | 2004-06-03 | Enzon Pharmaceuticals, Inc. | Prodrugs of vancomycin with hydrolysis resistant polymer linkers |
JP2006516548A (en) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | Drug delivery from rapidly gelled polymer compositions |
-
2003
- 2003-12-30 JP JP2005508640A patent/JP2006516548A/en not_active Withdrawn
- 2003-12-30 EP EP03800334A patent/EP1594459B1/en not_active Expired - Lifetime
- 2003-12-30 EP EP20100153526 patent/EP2181704B1/en not_active Expired - Lifetime
- 2003-12-30 AT AT03800334T patent/ATE457716T1/en not_active IP Right Cessation
- 2003-12-30 DE DE60331367T patent/DE60331367D1/en not_active Expired - Lifetime
- 2003-12-30 CA CA2511521A patent/CA2511521C/en not_active Expired - Fee Related
- 2003-12-30 WO PCT/US2003/041580 patent/WO2004060346A2/en active Application Filing
- 2003-12-30 US US10/749,117 patent/US20040225077A1/en not_active Abandoned
- 2003-12-30 AU AU2003300076A patent/AU2003300076C1/en not_active Ceased
-
2006
- 2006-05-04 HK HK06105282.0A patent/HK1083067A1/en not_active IP Right Cessation
-
2008
- 2008-10-28 US US12/259,916 patent/US20090192214A1/en not_active Abandoned
-
2011
- 2011-03-24 JP JP2011065148A patent/JP2011173887A/en active Pending
-
2012
- 2012-05-01 US US13/461,424 patent/US9326934B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE457716T1 (en) | 2010-03-15 |
EP1594459A2 (en) | 2005-11-16 |
AU2003300076B2 (en) | 2009-07-30 |
HK1083067A1 (en) | 2006-06-23 |
JP2011173887A (en) | 2011-09-08 |
JP2006516548A (en) | 2006-07-06 |
EP2181704B1 (en) | 2015-05-06 |
WO2004060346A2 (en) | 2004-07-22 |
US20040225077A1 (en) | 2004-11-11 |
DE60331367D1 (en) | 2010-04-01 |
AU2003300076C1 (en) | 2010-03-04 |
EP2181704A3 (en) | 2011-08-17 |
EP2181704A2 (en) | 2010-05-05 |
US20120252905A1 (en) | 2012-10-04 |
US20090192214A1 (en) | 2009-07-30 |
CA2511521C (en) | 2012-02-07 |
AU2003300076A1 (en) | 2004-07-29 |
WO2004060346A3 (en) | 2004-11-04 |
US9326934B2 (en) | 2016-05-03 |
EP1594459B1 (en) | 2010-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2511521A1 (en) | Drug delivery from rapid gelling polymer composition | |
JP2006516548A5 (en) | ||
US6316522B1 (en) | Bioresorbable hydrogel compositions for implantable prostheses | |
EP1968486B1 (en) | Room temperature-curable polymers | |
EP1100380B1 (en) | Bioabsorbable blends and surgical articles therefrom | |
US8840876B2 (en) | Antimicrobial polymer compositions and the use thereof | |
US7879356B2 (en) | Polymeric compositions | |
EP2629762B1 (en) | Pendant hydrophile bearing biodegradable compositions and related devices | |
US7795467B1 (en) | Bioabsorbable, biobeneficial polyurethanes for use in medical devices | |
US8273828B2 (en) | Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation | |
WO2005112587A3 (en) | Wound healing polymer compositions and methods for use thereof | |
US20210128795A1 (en) | Spiral coated stent with controllable gradient degradation, preparation method thereof and application thereof | |
CA2948357A1 (en) | Bioadhesive compounds and methods of synthesis and use | |
CA2751570A1 (en) | Multibranched bioadhesive compounds and synthetic methods therefor | |
WO2002085337B1 (en) | Micellar drug delivery systems for hydrophobic drugs | |
KR101838303B1 (en) | Reconstitutable reverse thermal gelling polymers | |
US20170369628A1 (en) | Biodegradable polymer | |
US6177094B1 (en) | Bioabsorbable blends and coating composition containing same | |
EP3435988B1 (en) | Drug-containing particulate composition with cationic agent, associated medical devices, and methods for treatment | |
CA2092646A1 (en) | Bioabsorbable blends of a bioabsorbable copolymer and a poly(oxyalkylene) | |
EP3197964B1 (en) | Medical composition | |
US20220111115A1 (en) | A bone cement composition | |
CN113082299B (en) | Degradable porous PVA/starch biological membrane and preparation method thereof | |
EP2890305A1 (en) | Mono-layer thin film adhesive compounds | |
WO2013154570A1 (en) | Synthetic mechanical hemostatic composition, method of making and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20180102 |